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1 Abstract
The chemokines CX3CL1 and CXCL16 and their receptors CX3CR1 and CXCR6 are
described in vascular inflammation and inflammatory cell recruitment. CX3CL1 and
CXCL16 are transmembrane surface proteins on endothelial cells inducing firm adhesion
of leukocytes via the interaction with their receptors. After shedding from the cell surface
by the metalloproteinases ADAM10 and ADAM17, they act as soluble chemoattractants
for CX3CR1- and CXCR6-expressing leukocytes, respectively. 
Here, it was demonstrated that expression of transmembrane CX3CL1 on endothelial
cells promotes leukocyte transendothelial migration, and details of the underlying
mechanisms using mutated CX3CR1 variants were elucidated. The DRY motif required
for Gi-protein-coupling was mutated to DNY, which abolished the intracellular calcium
release in response to CX3CL1, but did neither affect CX3CL1 binding nor uptake.
Truncation of the C-terminus reduced ligand uptake, but not ligand binding and calcium
responses. Both variants effectively mediated firm cell adhesion, but not chemotaxis
towards soluble CX3CL1. Furthermore, they failed to induce transmigration, but
mediated retention of leukocytes on the CX3CL1-expressing cell layer. Pharmacologic
and transcriptional inhibition of ADAM10 led to reduced shedding of transmembrane
CX3CL1, which was associated with an almost complete suppression of transmigration
in response to transmembrane CX3CL1. These results indicate a multistep process of
leukocyte recruitment by transmembrane CX3CL1 involving adhesion, signaling,
initiation of transmigration, and finally proteolytic release of the transmigrating
leukocytes.   
In contrast, transmembrane CXCL16 did not promote adhesion of CXCR6-expressing
cells, while soluble CXCL16 mediated chemotaxis. CXCR6 bears a DRF instead of the
DRY motif. Since this mutation is implicated in the constitutive activity of other
receptors, the DRF of CXCR6 was changed into DRY and DNF. Reconstitution of the
DRY motif did not affect ligand binding and resulted in a slight decrease in calcium
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signaling, whereas the mutation into DNF abolished calcium signaling. Both mutated
receptors still failed to induce adhesion to CXCL16-expressing cells. Signaling seemed
to depend on the arginine residue but not on the tyrosine/phenylalanine residue in DRY/
F. These results indicate that CXCL16 predominantly functions as a soluble chemokine.
Furthermore, cell recruitment by transmembrane chemokines differs. While CX3CL1
induces signaling-independent adhesion and signaling-dependent transmigration,
CXCL16 does not induce adhesion, but chemotaxis. 
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2 Introduction 
Inflammation is a fundamental defense reaction caused by tissue damage or injury. Its
primary purpose is the protection of the organism by removing or neutralizing injurious
agents and repairing the surrounding tissue. The inflammatory response involves three
major stages: first, dilation of the blood vessel leading to an increase of blood flow;
second, structural changes in the microvascular system; and third, localized recruitment
of various leukocyte subsets to sites of inflammation. The current model of leukocyte
extravasation from the vasculature into inflamed tissue comprises several steps governed
by diverse molecules such as cytokines, adhesion molecules and chemokines acting as
either soluble mediators, membrane-expressed ligands or signal transducing receptors. 
2.1 Current model of leukocyte extravasation 
Leukocyte extravasation is a multistep process that consists of at least five major
stages, and is halted when any one of them is suppressed (see Figure 1). On recognition
of pathogens, resident cells like macrophages or dendritic cells undergo activation and
release pro-inflammatory cytokines like IL-1, TNFα and chemokines. Endothelial cells
of blood vessels near the site of infection start to express cellular adhesion molecules,
such as selectins, as a result of activation by these cytokines. 
The selectins (P, E, and L) are type 1 transmembrane glycoproteins that bind to
modified sialyl Lewis X (sLex) present in their ligands in a Ca2+-dependent fashion. L-
selectin is expressed by most leukocytes, whereas the E and P forms are expressed on
endothelial cells that were activated by proinflammatory stimuli. Binding of endothelial
E- and P-selectins to their corresponding ligands on the leukocytes slows down the
velocity of leukocytes in the bloodstream, leading to a rolling movement of the cells on
the vascular wall (reviewed in: [Barreiro et al., 2004]). 
As leukocytes start tethering to the vascular endothelium and their rolling velocity
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slows, integrins are activated upon encountering immobilized chemokines and integrin
ligands exposed on the apical endothelial surface [Campbell et al., 1998]. This activation
step enables the arrest of leukocytes and their subsequent firm adhesion to the
endothelium under physiological flow conditions. 
Figure 1: Multiple steps are necessary for leukocyte extravasation. Leukocytes
recognize and bind selectins that are expressed by cytokine-activated endothelial
cells leading to a rolling movement. Subsequently, integrins become activated and
undergo a conformational change. In the next step integrins, adhesion molecules
and chemokine receptors bind to their respective ligands on the endothelial cell sur-
face, leading to firm adhesion. Then, leukocytes crawl on the cell surface in search
of an appropriate site for transmigration. After protrusion between two adjacent en-
dothelial cells transmigration towards an increasing chemokine-gradient occurs.
Figure modified after: [Man et al., 2007]. 
Integrins comprise a family of 24 heterodimeric receptors, each of which is composed
of an α-subunit and a β-subunit. These molecules dynamically alter their adhesive
properties through conformational changes [Beglova et al., 2002; Nishida et al., 2006].
The most relevant integrins for leukocyte adhesion to the endothelium are members of
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the β2 subfamily, particularly LFA-1 (αLβ2), as well as VLA-4 (α4β1). 
Most of the ligands are transmembrane proteins that belong to the immunoglobulin
superfamily, such as endothelial intercellular adhesion molecule-1 (ICAM-1, ligand to
LFA-1) and vascular cell adhesion molecule-1 (VCAM-1, ligand to VLA-4) [Gahmberg
et al., 1990]. 
Chemoattractants stimulate the directional leukocyte migration called chemotaxis.
Chemokines are small chemotactic polypeptides that induce leukocyte migration towards
increasing concentration gradients of chemokines. However, soluble chemokine
gradients are unlikely to exist at the luminal endothelial surface, since they could be
easily washed away. Therefore, it has been proposed that chemokines could act as bound
form to exert proadhesive and migratory effects on leukocytes in the lumen of blood
vessels. There are several chemokines that are known to be immobilized on the
endothelial cell surface by binding to glycosaminoglycans, like IL-8 and RANTES [Rot
et al., 1992; Tanaka et al., 1993]. Additionally, there exist two special chemokines
termed CX3CL1 and CXCL16 that are produced as membrane-anchored molecules by
the endothelium, and can be shed to a soluble form by metalloproteinases of the ADAM
(a disintegrin and metalloprotease) family [Bazan et al., 1997; Garton et al., 2001;
Hundhausen et al., 2003]. CX3CL1 and CXCL16 likely play a role as transmembrane
adhesion molecules as well as soluble chemoattractants. 
Subsequent to firm adhesion, leukocytes transmigrate through the endothelium without
irreversibly impairing its integrity. Two routes exist that the cells can use: they can either
move between the endothelial cells (paracellular) or they can migrate through an
endothelial cell (transcellular). It is still unclear to which extent each of the ways is
involved in transmigration. For paracellular transmigration, leukocytes encounter tight
junctions and adherence junctions and engage other transmembrane receptors, including
junctional molecules such as platelet/endothelial cell adhesion molecule-1 (PECAM-1),
members of the junctional adhesion molecule (JAM) family, and CD99, which contribute
to sequential steps of the transmigration process [Muller et al., 1993; Martin-Padura et
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al., 1998; Schenkel et al., 2002]. 
Transmigration requires a morphological change of leukocytes. They become
polarized with at least two regions that can be identified: the cell front and the cellular
uropod [del Pozo et al., 1995]. This allows the cell to coordinate the intracellular forces
that are needed for directed cell crawling [Geiger and Bershadsky, 2002]. Once the
leukocyte has encountered an appropriate site for transmigration, it extends pseudopods
between two adjacent cells. During the transmigration process, chemokine receptors
polarize on the leading edge, resulting in a functional specialization of this cell domain in
signal transduction [Nieto et al., 1997]. Since transmigration is mediated by intracellular
phosphorylation signals through chemokine receptors, this re-organization may act as a
sensor mechanism for chemokine-guided cell trafficking [Bokoch, 1995]. 
2.2 Chemokines 
The superfamily of chemokines consists of at least 42 small chemotactic cytokines.
They share structural characteristics such as the size (8-10 kDa) and the presence of
conserved cysteine residues in the N-terminal region forming their 3-dimensional shape.
Chemokines are classified into four groups according to the number and position of these
cysteine residues. CXC-chemokines are characterized by the presence of one amino acid
between the first two cysteines, whereas in CC-chemokines the first two cysteines are
adjacent to each other. The C-chemokine family only contains two of the four conserved
cysteine residues, and in the CX3C-chemokine family, with its only member CX3CL1,
three amino acids separate the first two cysteines (see Figure 2). 
Chemokines consist of an elongated N-terminus that includes the first cysteine.
Following the first two cysteines, the structure forms a so-called N-loop consisting of
approximately ten residues that is succeeded by a sequence of α-helices and two
antiparallel β-sheets interrupted by loops. The so-called 30- and 50-loops contain the
third and fourth cysteine residue. Due to disulfide bonds between the first and the third
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and between the second and the fourth cysteine the molecule is stabilized. The sequence
identities between different chemokines vary from less than 20% to over 90%. 
Figure 2: Chemokines are divided into four groups based on their first two
cystein residues. Chemokines are subdivided into four groups based on the posi-
tioning of the first two conserved cysteine residues. In CXC α chemokine family,
one amino acid is located between the first two chemokines; in CC β chemokine
family, the first two cysteines are adjacent to each other; in CX3C δ chemokine
family, there are three interfering amino acids; in C γ chemokine family, only two
of the conserved cysteine residues are present. Figure modified after: [Rostene et
al., 2007]. 
The three-dimensional structure of each monomer is virtually identical, but the
quaternary structure of chemokines differs for each subfamily. Structural studies reveal
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several regions of chemokines to be involved in receptor binding and function, with the
N-terminal region playing an important role [Onuffer and Horuk, 2002; Allen et al.,
2007]. 
Some chemokines are considered pro-inflammatory and can be induced during an
immune response to promote cells of the immune system to a site of infection, while
others are considered homeostatic and are involved in controlling the migration of cells
during normal processes of tissue maintenance or development. 
2.3 Chemokine receptors 
Chemokines exert their biological effects by interacting with G-protein-linked 7-
transmembrane-spanning receptors, called chemokine receptors that are selectively found
on the surfaces of their target cells. These chemokine receptors are part of a much bigger
superfamily of G-protein-coupled receptors that include receptors for hormones,
neurotransmitters, paracrine substances, inflammatory mediators, certain proteases, taste
and odorant molecules, and even photons and calcium ions. 
G-protein-coupled receptors are associated with a heterotrimeric G-protein (guanine
nucleotide-binding protein) consisting of three subunits (α, β and γ). On conformational
changes by ligand-binding, the receptor can act as guanine nucleotide exchange factor
and activate the G-protein by exchanging its bound GDP to GTP. The α-subunit with the
bound GTP then dissociates from the β- and γ-subunits and further affects intracellular
signaling depending on the α-subunit type. 
There are two general signal transduction pathways involved in G-protein-coupled
receptors: cAMP signal pathway and phosphatidylinositol signal pathway. Gαi, or
inhibitory regulative G-protein, associated signaling leads to an inhibition of adenylate
cyclase that catalyzes the formation of cAMP from ATP. In phosphatidylinositol
signaling, phosphatidylinositol 4,5-bisphosphate (PIP2) is cleaved into the second
messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) by
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phospholipase C. IP3 then activates Ca2+-release channels in endoplasmatic reticulum
membranes, where it can bind to calmodulin or can be used to activate protein kinase C
together with DAG. Protein kinase C, in turn, catalyzes the phosphorylation of several
cellular proteins, resulting in altered protein activity. 
GPCRs become desensitized after prolonged exposition to their ligands. G-protein
receptor kinases can phosphorylate the intracellular part of active receptors, leading to
the binding of β-arrestin that either prevents the receptor from binding to its ligand or, as
in the most cases, promotes the removal of the receptor from the membrane via clathrin-
mediated endocytosis, called internalization. When the receptor is dephosphorylated in
the acidic microenvironment, it can be re-expressed at the cell surface [Krueger et al.,
1997; Laporte et al., 1999]
G-protein-coupled receptors are grouped into six classes according to their sequence
homology and functional similarity, with the largest group being class A or rhodopsin-
like GPCRs. Chemokine receptors belong to the group of class A GPCR. To date 19
distinct chemokine receptors have been described in mammals, and they are thought to
predominantly couple to the Gαi -subunit. 
Chemokine receptors are further subdivided into different families that correspond to
the 4 distinct subfamilies of chemokines they bind (CXC chemokine receptors, CC
chemokine receptors, CX3C chemokine receptors and XC chemokine receptors). Each of
the chemokine receptors binds only a single class of chemokines, although they can bind
several members of the same class with high affinity. Furthermore, several chemokines
can bind and activate a number of chemokine receptors. 
2.3.1 Structural characteristics 
Chemokine receptors measure approximately 350 amino acids in length. A short
extracellular N-terminus is acidic overall and may be sulfated on tyrosine residues and
contains N-linked glycosylation sites. Seven α-helical transmembrane domains - with
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three intracellular and three extracellular connecting loops composed of hydrophilic
amino acids - are oriented perpendicularly to the plasma membrane. A disulfide bond
links highly conserved cysteines in extracellular loops 1 and 2. G-proteins are coupled
through the C-terminus segment and possibly through the third intracellular loop
[Murdoch and Finn, 2000]. 
Throughout the GPCR super-family, several highly conserved motifs have been
identified. The aspartate-arginine-tyrosine (DRY) sequence in the second intracellular
loop is required for activation of Gi-proteins, whereas the NPX2-3Y motif located in the
seventh transmembrane region of most GPCRs contributes to ligand binding, activation
and internalization of the receptor [Slice et al., 1994; Arora et al., 1995]. Additionally,
GPCRs typically carry several serine residues within the intracellular C-terminal region,
which can become phosphorylated by G-protein-coupled receptor kinases and mediate
interaction with β-arrestins and desensitization of the receptor towards its ligand [Kim
and Caron, 2008]. Table 1 shows the conserved motifs mentioned above and their
functional relevance as shown for other GPCRs in which the motifs were altered. 
2.4 CX3CL1 and its receptor CX3CR1 
2.4.1 Fractalkine 
CX3CL1 (fractalkine) is expressed as a cell surface protein on dendritic, epithelial,
neuronal and most prominently on endothelial cells [Bazan et al., 1997]. CX3CL1 (like
CXCL16) is an unique member of the chemokine family as it occurs in a membrane-
tethered and a soluble form. It is expressed as type I transmembrane protein (N-terminus
extracellular), and its ectodomain can be proteolytically cleaved from the cell surface.
This process is known as shedding. ADAM10 is implicated in constitutive shedding of
fractalkine [Hundhausen et al., 2003], whereas ADAM17 mediates PMA-induced
shedding [Garton et al., 2001]. 
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Table 1: Conserved motifs in GPCR class A. Conserved motifs in the G-protein-
coupled receptor class A were mutated in a variety of receptors. The table shows
the consequence of altering motifs. 
Motif Receptor Consequence Reference
DRY rhodopsin impaired stimulation of 
transducin
[Acharya and Karnik, 1996]
gonadotropin-releasing 
hormone receptor
impaired internalization 
and IP3 response
[Arora et al., 1997]
CXCR4 loss of activity [Berchiche et al., 2007]
oxytocin receptor constitutive activity [Fanelli et al., 1999]
CCR5 loss of activity [Gosling et al., 1997]
CCR5 loss of G-protein 
activation
[Lagane et al., 2005]
mCX3CR1 impaired signaling and 
chemotaxis
[Haskell et al., 1999]
dopamine D2 and D3 
receptors 
impaired signaling [Kim et al., 2008]
alpha 1B adrenergic 
receptor 
no G-protein coupling, 
constitutive 
desensitization
[Wilbanks et al., 2002]
angiotensin II type 1A 
receptor
no G-protein coupling, 
constitutive 
desensitization
[Wilbanks et al., 2002]
vasopressin receptor non-signaling, constitutive
desensitization
[Barak et al., 2001]
V2 vasopressin receptor no G-protein stimulation [Rosenthal et al., 1993]
M1/M2 muscarinic 
receptor
decrease in signaling [Zhu et al., 1994]
alpha1B-adrenergic 
receptor
loss of receptor-mediated 
response
[Scheer et al., 2000]
histamine H2 receptor loss of basal activity [Alewijnse et al., 2000]
NPX2-3Y beta-1-adrenergic 
receptor
impaired internalization 
and binding 
[Barak et al., 1995]
angiotensin II receptor impaired binding and sig-
nal transduction
[Hunyady et al., 1995]
gastrin-releasing hor-
mone receptor
no impairments [Slice et al., 1994]
truncation IL8Rbeta migration impairment [Ben-Baruch et al., 1995]
CCR5 sustained calcium 
response
[Kraft et al., 2001]
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The membrane-tethered form consists of a chemokine domain anchored to the plasma
membrane through an extended mucin-like stalk, a transmembrane helix and an
intracellular domain. Analysis of the C-terminal cleavage fragments, which remain in the
cell membrane, reveals multiple cleavage sites used by ADAM10 [Hundhausen et al.,
2007]. 
Compared to other chemokines, CX3CL1 has at least three unique structural features
that may mediate its function as an adhesion molecule. It is a transmembrane molecule
with a cytoplasmic tail that may participate in signal transduction, it has a mucin domain,
and it has a three-dimensional structure that is slightly different from other chemokines
[Mizoue et al., 1999]. The fractalkine mucin domain is a 26 nm long stalk that functions
in extending the chemokine domain away from the cell surface and is functionally
similar to the stalk regions of the selectin family of molecules. It does not contribute to
fractalkine binding affinity and efficacy for stimulating calcium mobilization in
CX3CR1-expressing cells [Harrison et al., 2001]. 
2.4.2 CX3CR1 
CX3CL1 binds to a single receptor (CX3CR1, also known as V28) that is expressed
on several leukocyte subsets including monocytes, NK cells, T cell populations, dendritic
cells and microglia [Imai et al., 1997; Combadiere et al., 1998; Dichmann et al., 2001].
CX3CR1 belongs, as all chemokine receptors, to the group of G-protein-coupled
heptahelical receptors and couples to Gi/o [Wong, 2003]. 
The CX3CR1 gene is multi-exonic with the ORF residing entirely in a single exon,
like most chemokine receptors. There are three functionally independent promoter
regions that direct CX3CR1 transcription, giving rise to three different transcripts that
may be expressed selectively in different cell populations [Garin et al., 2002]. Four
naturally occurring receptor variants (T57A, V122I, V249I and T280M) are described in
humans [Faure et al., 2000]. While M280 is never found in the absence of I249, the
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converse is not true [McDermott et al., 2003]. The I249 allele has been associated with
reduced fractalkine binding affinity as well as with reduced risk for acute coronary
events and improved endothelium-dependent vasodilation [McDermott et al., 2001;
Moatti et al., 2001]. 
Figure 3: Schematic view of CX3CR1. CX3CR1 is a seven-transmembrane G-
protein-coupled receptor belonging to the family of chemokine receptors. Targeted
mutation of selected acidic amino acid residues demonstrated that the binding activ-
ity of CX3CR1 is critically dependent on the two negatively charged residues
Asp25 and Glu254 located on the N-terminal domain and third extracellular loop,
respectively. Furthermore, the initial interaction triggers the engagement of Glu13,
Asp16, and Asp266, which are necessary for CX3CR1 activation [Chen et al.,
2006]. The numbers specify the positions of the various amino acid residues in the
protein. The transmembrane domains are illustrated by the cylindrical arrangements
of the amino acids. 
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2.4.3 Consequences of CX3CR1-CX3CL1 interaction 
Transmembrane as well as soluble CX3CL1 binds to CX3CR1. However, both
CX3CL1 variants mediate different steps of the recruitment process and employ distinct
mechanisms. Transmembrane CX3CL1 serves as an adhesion molecule, mediating
enhanced leukocyte adhesion to endothelial cells under flow conditions. This activity is
largely independent of CX3CR1-mediated Gi-protein activation and predominantly a
result of the physical interaction of the transmembrane chemokine with its receptor
[Fong et al., 1998]. By contrast, soluble CX3CL1 acts as a chemoattractant inducing
directional cell migration via CX3CR1 signaling and activation of Gi -proteins [Imai et
al., 1997]. 
Fractalkine expression is upregulated after stimulation with IL-1β, LPS, IFNγ and
TNFα, and it can induce its own expression, which is both mediated via the NF-κB
pathway [Garcia et al., 2000]. Treatment with CX3CL1 increases endothelial cell
proliferation in a dose- and time-dependent manner [Lee et al., 2006], and the molecule
may serve as survival factor for microglial cells and monocytes [Boehme et al., 2000;
Landsman et al., 2009]. 
Receptor activation by soluble fractalkine induces activation of Akt and p53, ERK and
eNOS phosphorylation in a time- and dose-dependent manner, and nuclear translocation
of NF-κB. It does not induce SAPK/JNK and p38 phosphorylation. Furthermore,
stimulation with CX3CL1 induces a calcium flux response in CX3CR1 expressing cells
in a concentration-dependent manner. The G-protein-coupled receptor inhibitor pertussis
toxin (PTX) efficiently blocks fractalkine-induced phosphorylation of ERK, Akt and
eNOS, suggesting that the receptor is linked to Gi-proteins [Lee et al., 2006]. 
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Figure 4: Schematic view of CX3CR1 signaling. On binding of CX3CL1 to its
receptor CX3CR1, G-protein subunit α uncouples, and PI3-kinase (PI3K) and Phos-
pholipase C (PLC) become activated. PLC activation leads to diacylglycerol (DAG)
and inositol 1,4,5-trisphosphate (IP3) formation, which stimulate calcium release
from the endoplasmatic reticulum and subsequent activation of calcineurin, protein
kinase C (PKC) and endothelial nitric oxide synthase (eNOS). PI3K activation
leads to activation of mitogen-activated protein kinase (MAP kinase) pathway and
Akt and subsequent translocation of NF-κB to the nucleus. 
2.4.4 CX3CL1 and CX3CR1 in clinical disease 
Accumulating evidence suggests that CX3CL1-CX3CR1 interaction contributes to the
development and the progression of many inflammatory diseases, some of which are
described in more detail in the following. 
Fractalkine is suggested to be involved in atherosclerosis and cardiovascular patho-
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physiology. In some human advanced atherosclerotic lesions, high levels of fractalkine
mRNA expression have been observed [Greaves et al., 2001]. Apolipoprotein E-deficient
(apoE-/-) mice show upregulated CX3CL1 expression, whereas apoE-/- mice crossing
with CX3CR1-/- mice resulted in a decreased atherosclerotic lesion formation
[Combadière et al., 2003; Lesnik et al., 2003]. Gene polymorphisms V249I and T280M
of human CX3CR1 have been reported to be a genetic risk factor for coronary artery
disease, whereas CX3CR1-V249I/T280M heterozygosity is associated with a reduced
risk of acute coronary events [McDermott et al., 2001; Moatti et al., 2001]. 
Additionally, fractalkine has been reported to play a role in human renal diseases
(glomerulonephritis, renal tumours, and renal transplants) and in kidney disease in
animal models. The expression of fractalkine and the presence of CX3CR1-expressing
cells have been demonstrated in patients with various types of nephropathies [Furuichi et
al., 2001; Cockwell et al., 2002]. Anti-CX3CR1 antibody treatment blocked leukocyte
infiltration into the glomeruli and improved renal function, suggesting a role for
fractalkine and CX3CR1-expressing cells in the pathogenesis of human
glomerulonephritis [Feng et al., 1999]. 
Furthermore, an increased expression of fractalkine has been detected in lymph nodes
and brain tissue from patients with HIV. The increased expression of CX3CL1 is
associated with a protection of neurons from two HIV-1 neurotoxins, but induces the
depletion of CX3CR1-positive T-helper cells by contact with dendritic cells [Tong et al.,
2000; Foussat et al., 2001]. Since HIV-infected patients homozygous for CX3CR1-
I249M280 progress to AIDS more rapidly than do those with other haplotypes, it has
been concluded that the specific polymorphism, CX3CR1-I249M280, is a genetic risk
factor in HIV infection [Faure et al., 2000]. 
It still remains unclear whether these diseases are mediated by either the
transmembrane, the soluble or both variants of CX3CL1. The investigation of each
variant is complicated by the fact that transmembrane CX3CL1 is converted into soluble
CX3CL1 by limited proteolysis. This process is called shedding and involves several cell
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surface enzymes called sheddases. A class of sheddases implicated in the shedding
process of CX3CL1 is the ADAM (a disintegrin and metalloproteinase) family with its
members ADAM10 (kuzbanian) and ADAM17 (TACE for TNFα converting enzyme). 
2.5 CXCL16 and its receptor CXCR6 
2.5.1 CXCL16 
CXCL16 is a CXC α chemokine, but shares characteristics of CC chemokines (strong
homology to MIP-1β, long loop between Cys2 and Cys3 like CTAK and TECK, and 6
Cys-residues like 6-C-Kine), and shows structural similarities to CX3CL1 like a
transmembrane region and a chemokine domain suspended by a mucin-like stalk
[Wilbanks et al., 2001]. Initially, CXCL16 was described as scavenger receptor for
oxidized low density lipoprotein (ox-LDL), phosphatidylserine, dextran sulphate and
bacteria under the name of SR-PSOX (scavenger receptor that binds phosphatidylserine
and oxidized lipoprotein) [Shimaoka et al., 2000]. SR-PSOX specifically binds,
internalizes and degrades ox-LDL leading to foam cell transformation implicated in the
process of atherogenesis [Ross, 1993]. 
CXCL16 is predominantly expressed by antigen-presenting cells, including subsets of
CD19+ B cells, CD14+ monocytes/macrophages, dendritic cells, aortic smooth muscle
cells and by cells in the splenic red pulp [Matloubian et al., 2000; Wilbanks et al., 2001;
Chandrasekar et al., 2004]. Like fractalkine, CXCL16 can be shed by ADAM10 to form
a soluble chemokine that induces chemotaxis of activated T-cells and bone marrow
plasma cells via its receptor CXCR6 [Matloubian et al., 2000; Nakayama et al., 2003;
Abel et al., 2004]. 
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2.5.2 CXCR6 
CXCR6 (also called Bonzo), like all chemokine receptors a G-protein-coupled
heptahelical receptor, is the only known receptor for CXCL16. It is expressed on CD4+
T-helper 1, CD8+ T-cytotoxic and T-regulatory 1 subsets of T-cells, smooth muscle
cells, dendritic cells, B-cells, macrophages, and subsets of natural killer cells
[Matloubian et al., 2000; Sharron et al., 2000; Kim et al., 2001; Wilbanks et al., 2001;
Hofnagel et al., 2002; Sato et al., 2005]. CXCR6 was firstly described as a fusion co-
factor for HIV-1/SIV [Deng et al., 1997], and the polymorphism CXCR6-3E/K is
implicated in a prolonged survival time from Pneumocystis carinii pneumonia in HIV-
positive individuals. In contrast, patients with the polymorphism showed impaired viral
suppression after initiation of Highly Active Anti-Retroviral Therapy (HAART) [Passam
et al., 2007]. 
Instead of the conserved DRY-motif that is common for G-protein-coupled receptors,
CXCR6 has a DRF-motif. This alteration was already described for the arthropod 5-
HT2βPan receptor and was implicated in its constitutive activity [Clark et al., 2004]. The
conserved NPX2-3Y motif is unaltered. 
2.5.3 Consequences of CXCL16-CXCR6 interaction 
CXCL16 mediates adhesion, chemotaxis and calcium signaling in CXCR6-expressing
cells [Wilbanks et al., 2001]. As described for CX3CL1, both variants - soluble and
transmembrane - might mediate different steps in the process of cell extravasation.
CXCL16 is a potent activator of NF-κB, but fails to regulate its own expression,
indicating that CXCL16, unlike CX3CL1, is not a NF-κB-responsive chemokine. Both
IL-1 and TNFα fail to influence CXCL16 expression in human aortic smooth muscle
cells and umbilical vein endothelial cells [Hofnagel et al., 2002]. 
CXCR6 signals via PI3K, Akt, IκK and IκB phosphorylation. Binding of CXCL16
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mediates NF-κB activation via Akt/PKB, leading to increased proliferation of human
aortic smooth muscle cells. Therefore, treatment with CXCL16 does not induce cell
death, but promotes cell survival and proliferation. Additionally, CXCL16 binding leads
to Bad (Bcl-2-Antagonist of Cell Death)-phosphorylation, indicating its role as anti-
apoptotic chemokine. This suggests that chemokines not only play a role in extravasation
processes, but also in cell survival and angiogenesis [Chandrasekar et al., 2004]. 
2.6 ADAMs 
ADAMs are type I transmembrane proteins and belong to the metzincin superfamily of
zinc-dependent proteases. They generally consist of about 750-800 amino acids. The N-
terminal extracellular pro-domain is followed by a highly conserved metalloprotease
domain. The active site for the proteolytic cleavage contains HEXGHNLGXXHD and
contains a catalytically essential zinc-ion, which is chelated by the three conserved
histidin-residues. A conserved methionine residue beneath the active site metal, as part of
a ”Met-turn”, loops the polypeptide chain beneath the catalytic zinc ion, forming a
hydrophobic floor to the Zn2+ ion binding site [Stocker and Bode, 1995]. The disintegrin-
domain might be a ligand for integrins and is succeeded by a cysteine-rich potential cell
fusion region. The C-terminal cytoplasmic domain does not share significant sequence
similarities. Some of them contain putative consensus sequences for binding to sarcoma
(Src) and Src-related SH3 domains [Wolfsberg and White, 1996]. 
Although a single sheddase may shed a variety of substances, multiple sheddases can
cleave the same substrate resulting in different consequences. More than 40 type-1 cell
surface proteins are known substrates for ADAMs (reviewed in: [Pruessmeyer and
Ludwig, 2008]). CX3CL1 can be cleaved from the cell surface by two distinct enzyme
activities. ADAM10 is implicated in the constitutive shedding of CX3CL1 of
unstimulated cells, whereas cleavage by ADAM17 is inducible by phorbol esters such as
phorbol 12-myristate 13-acetate (PMA) [Garton et al., 2001; Hundhausen et al., 2003]. 
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ADAM10 and ADAM17 are upregulated in activated endothelium and play a role in
ectodomain shedding of adhesion molecules during leukocyte recruitment [Boulday et
al., 2001]. Since CX3CL1 acts as an adhesion molecule that is upregulated in activated
endothelium, it can be cleaved by ADAM10 or 17 to form an additional soluble
chemoattractant to recruit more inflammatory cells as well as to allow abrogation of firm
adhesion in order to let transmigration take place. 
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3 Aim of this thesis 
This thesis aimed to characterize the role of CX3CL1 in distinct steps of leukocyte
recruitment and to elucidate the mechanism of CX3CL1-mediated cell recruitment.
Primary cells (PBMC) were investigated for adhesion and chemotaxis in response to
soluble and transmembrane CX3CL1 expression on endothelial cells. Then, a model
system of cell lines for adhesion and chemotaxis/transmigration induced by CX3CL1
was established and confirmed to show the same behavior as primary cells.  
In order to determine which structural characteristics are important, mutated receptor
variants altering the DRY motif in the second intracellular loop, the NPX2-3Y motif in
the seventh transmembrane domain, and deleting all C-terminal serine residues by
truncation were generated. The effect of mutating these highly conserved regions was
studied in functional assays like binding, ligand uptake, signaling, adhesion,
transmigration, and pseudopod formation. 
Since the activity of ADAM10 and 17 is supposed to be required in efficient leukocyte
extravasation, it was examined whether the metalloproteases ADAM10 and 17 are
required in CX3CL1-mediated function using pharmacological inhibitors to the proteases
and shRNA silencing. 
CXCL16 is the only other chemokine that is expressed as transmembrane as well as
soluble form. This raised the question whether the findings concerning CX3CR1 are
similar for CXCR6. Therefore, the CXCL16-CXCR6 interaction was examined in
functional assays like adhesion and chemotaxis. Furthermore, the unusual DRF motif of
CXCR6 was altered and the functional consequence of the receptor variants was studied. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Cell Culture 
Media, supplements and reagents used for cell culture were purchased from PAA
(Pasching, Austria) if not stated otherwise. Cells were cultured on cell culture
plasticware from Sarstedt (Nuembrecht, Germany). 
4.1.2 Primer 
All primers were ordered from Eurofins MWG Operon (Ebersberg, Germany). They
were diluted to a final concentration of 100 pmol/µl. 
Primer Sequence 
hCX3CR1 sense 5’- gaattcaccatggatcagttccctgaatcagt -3’ 
hCX3CR1 antisense 5’- ctcgagtcagagaaggagcaatgcatctccatca -3’ 
hCX3CR1 S319X antisense 5’- cggtgaagaatatgcttccaaaaaagccgta -3’ 
hCX3CR1 R127N sense 5’- tcatcagcattgataactacctggccatcgtcct -3’ 
hCX3CR1 R127N antisense 5’- cggtgatgaagaatatgcttccaaaaaagccgta -3’ 
hCX3CR1 N289A sense 5’- cctggctcctctcatctatgcattt -3’ 
hCX3CR1 N289A and Y293A antisense 5’- caacaatggctaaatgcaaccgtct -3’ 
hCX3CR1 Y293A sense 5’- cctgaatcctctcatcgctgcattt -3’ 
hCXCR6 sense 5’- gaattcaccatggcagagcatt-3’ 
hCXCR6 antisense 5’-ctcgagctataactggaacat-3’ 
hCXCR6 R127N sense 5’-cactgtggatcgttacattgta-3’ 
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hCXCR6 R127N antisense 5’-atgcaggtgaggatgagcat-3’ 
hCXCR6 F128Y sense 5’-atgcaggtgaggatgagcat-3’ 
hCXCR6 F128Y antisense 5’-atgcaggtgaggatgagcat-3’ 
4.1.3 Plasmids 
Name Backbone Restriction sites used 
hCX3CR1 pcDNA3.1+ EcoRI XhoI 
hCX3CR1-R127N pcDNA3.1+ EcoRI XhoI 
hCX3CR1-N289A pcDNA3.1+ EcoRI XhoI
hCX3CR1-Y293A pcDNA3.1+ EcoRI XhoI 
hCX3CR1-S319X pcDNA3.1+ EcoRI XhoI 
hCXCR6 pcDNA3.1+ EcoRI XhoI 
hCXCR6-R127N pcDNA3.1+ EcoRI XhoI 
hCXCR6-F128Y pcDNA3.1+ EcoRI XhoI
4.1.4 Antibodies 
Antibody Species Company Final Conc. Application
hCX3CR1-PE rat IgG2bκ MBL, Japan 1 µg/ml FACS 
isotype control-PE rat IgG2bκ Abcam 1 µg/ml FACS 
hCX3CL1 mouse IgG1 R&D Systems 10 µg/ml FACS, inhibition
hCX3CL1 mouse  R&D Systems 4 µg/ml ELISA
hCX3CL1-biotin mouse R&D Systems 0.3 µg/ml ELISA
ICAM-1 mouse IgG1 R&D Systems 10 µg/ml inhibition 
VCAM-1 mouse IgG1 R&D Systems 10 µg/ml inhibition 
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isotype control mouse IgG1 R&D Systems 10 µg/ml FACS, inhibition
hCXCR6-PE mouse IgG2b R&D Systems 5 µg/ml FACS 
isotype control-PE mouse IgG2b R&D Systems 5 µg/ml FACS 
6xHis-tag mouse IgG2b Abcam 4 µg/ml FACS
mouse-PE goat Jackson Immuno 2.5 µg/ml FACS
humanFc-PE goat Jackson Immuno 5 µg/ml FACS
4.1.5 Chemicals 
All chemicals were ordered from either Sigma-Aldrich (St.Louis, MO) or Roth
(Karlsruhe, Germany), if not specified otherwise. All enzymes for cloning were
purchased from Fermentas (St.Leon-Rot, Germany), if not specified otherwise. 
Name Company 
AlexaFluor647-labeled CX3CL1-CD Almac, Craigavon, UK 
AMAXA nucleofactor Lonza, Cologne, Germany 
Calcein-AM Biotium Inc., Hayward, CA 
Collagen G Biochrom AG, Berlin, Germany 
Collagenase II Sigma-Aldrich, St.Louis, MO 
CXCL16-CD Peprotech, Hamburg, Germany 
CXCL16-6xHis R&D Systems, Wiesbaden, Germany
CX3CL1-CD Peprotech, Hamburg, Germany 
Endothelial cell growth medium Promocell, Heidelberg, Germany 
Fluo-3-AM Molecular Probes, Karlsruhe, Germany 
Gel loading dye Fermentas, St.Leon-Rot, Germany 
G418 Calbiochem, Hamburg, Germany 
HBSS Gibco, Karlsruhe, Germany 
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HEPES Gibco, Karlsruhe, Germany 
IFNγ Peprotech, Hamburg, Germany 
Lipofectamine Invitrogen, Karlsruhe, Germany 
NucleoSpin extract II kit Macherey-Nagel, Dueren, Germany 
Pancoll Pan Biotech, Aidenbach, Germany 
pcDNA3.1+ Invitrogen, Karlsruhe, Germany 
Pertussis toxin Calbiochem, Hamburg, Germany 
Plasmid DNA purification kit Macherey-Nagel, Dueren, Germany 
Strep-POD Roche, Grenzach, Germany
TNFα Peprotech, Hamburg, Germany 
TOPO TA cloning kit Invitrogen, Karlsruhe, Germany 
4.1.6 Devices and Materials 
Device/Material Company 
AMAXA Nucleofactor Lonza, Cologne, Germany 
Avanti J-25 Beckman Coulter, Palo Alto, CA
Boyden chamber Neuroprobe, Gaithersburg, MD 
Cary Eclipse reader Varian, Palo Alto, CA 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
EasyCyte Mini Millipore, Billerica, MA 
FACSCalibur BD Biosciences, San Jose, CA 
FACSCanto BD Biosciences, San Jose, CA 
Fluorescence plate reader Tecan Genios Tecan, Maennedorf, Switzerland 
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Glass bottom dishes MatTek, Ashland, MA 
Hemacytometer Brand, Wertheim, Germany 
Leica DM-IL microscope Leica, Wetzlar, Germany 
Leica DM-IRB microscope Leica, Wetzlar, Germany 
LSM 7 Duo microscope Zeiss, Goettingen, Germany 
MaxiSorp ELISA plate Nunc, Langenselbold, Germany
µ-slide VI ibidi, Munich, Germany 
NanoDrop ND-1000 PEQLAB, Erlangen, Germany
Polycarbonate membrane Neuroprobe, Gaithersburg, MD 
Syringe pump Landgraf, Langenhagen, Germany 
TProfessional basic thermocycler Biometra, Goettingen, Germany 
Transwell filters Costar Corning, Schiphol-Rijk, Netherlands 
4.1.7 Inhibitors
The substance GW280264X is a metalloprotease inhibitor based on hydroxamat
(Figure 5). It was synthesized at GlaxoSmithKline (Stevenage, UK) and stored at 4°C in
a 10 mM stock in DMSO. GW280264 inhibits the proteolytic activity of ADAM17, and
to a smaller degree of ADAM10 [Ludwig et al., 2005].
Figure 5: Structure of GW280264X. The metalloprotease inhibitor is based on
hydroxamat and inhibits ADAM17 as well as ADAM10. The half maximal in-
hibitory concentration (IC50) is 8.0 nM for ADAM17 and 11.5 nM for ADAM10.
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Dynasore (3-Hydroxynaphthalene-2-carboxylic acid (3,4-dihydroxybenzylidene)
hydra-zide) was obtained from Tocris (Bristol, UK) and stored at -20°C at 100 mM in
DMSO. The working concentration was 100 µM. It is a small molecule GTPase inhibitor
that targets dynamin-1 and dynamin-2. Dynasore blocks dynamin-dependent
endocytosis, and scission of endocytic vesicle. It is cell-permable and blocks in a
reversible and noncompetitive manner [Macia et al., 2006].
Figure 6: Structure of Dynasore. The small molecule GTPase inhibitor Dynasore
blocks dynamin-1 and dynamin-2. The half maximal inhibitory concentration
(IC50) is  approximately 15 µM.
4.2 Methods 
4.2.1 Cell culture 
4.2.1.1 Maintenance of cells 
The human embryonic kidney cell line HEK293 (ATCC: CRL-1573) was grown in
DMEM medium supplemented with 1% penicillin and streptomycin and 10% FCS. The
human epithelial cell line ECV304 (ATCC: CRL-1998) was grown in M199 medium
supplemented with 1% penicillin and streptomycin and 10% FCS. The murine pre-B-cell
cell line L1.2 (Massachusetts Association of Technology Transfer, Tufts University,
Boston, MA) was grown in RPMI1640 medium supplemented with gentamycin, 10%
FCS, 1% HEPES, 1% pyruvate and β-mercaptoethanol. The primary human umbilical
4 Materials and Methods
31
vein endothelial cells were grown in Endothelial Cell Growth Medium including
Supplement. 
Cells were subcultured using trypsin-EDTA. To this purpose, cells were washed with
PBS and incubated with Trypsin-EDTA for 5 minutes at 37°C. Then, cells were
resuspended in PBS, centrifuged at 300×g, and seeded at 1:5 to 1:20. 
Cells were counted and viability of cells was tested using Trypan blue. 10 µl of cell
suspension was mixed with 10 µl 0.4% Trypan blue and given onto a hematocymeter.
Trypan blue exclusively stains dead cells blue. These cells were excluded in counting.
For freezing cells, confluent grown cells were washed with PBS and incubated with
Trypsin-EDTA for 5 minutes at 37°C. Subsequently, cells were washed with PBS,
centrifuged at 300×g at room temperature, and resuspended in 3 ml pre-cooled medium
with 20% FCS and 10% DMSO. 1 ml of cell suspension at a time was given into a
cryotube. Cells were then transferred on ice at -20°C over night, at -80°C for 3 days, and
at liquid nitrogen for final storage.
4.2.1.2 Transient transfection 
Different strategies were used to transiently transfect cells. HEK293 cells were
transfected with lipofectamine, while L1.2 cells were transfected using the AMAXA
system.
Lipofectamine. Cells were seeded in 6-well-plates and grown to 70% - 80%
confluency. Following complexes were prepared for transfection per well of a 6-well-
plate: 
1.5 µg DNA 
3 µl Lipofectamine 
100 µl serum-free medium 
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During the incubation of the reaction setup for 20 minutes at room temperature, cells
were washed and medium was exchanged. 100 µl of the complex solution were added to
each well drop by drop. Cells were incubated at 37°C in a CO2 incubator for 48 hours. 
AMAXA Nucleofactor. 2x106 cells were taken out of the flask, centrifuged at 300×g
for 5 minutes at room temperature and medium was removed. The cell pellet was
resuspended with the following solution: 
5 µg DNA 
18.1 µl Nucleofactor supplement 
81.8 µl Nucleofactor solution 
The cell/DNA suspension was then transferred into cuvettes, inserted into the
Nucleofactor device, and program P16 was applied. Immediately after the program was
finished, pre-warmed medium was added to the cuvettes, and the cells were gently
transferred into T25 flasks. Cells were incubated at 37°C in a CO2 incubator for 48 hours.
4.2.1.3 Stable transfection 
48 hours after transfection cells were selected for receptor expression using 1 mg/ml
G418 because only transfected cells are resistent to G418. For HEK293 cells medium
was changed every 3 days, and fresh G418 was added. L1.2 cells were tested for viability
every 3 days, and fresh G418 was added every 5 days. The remaining viable cells were
cultured to confluency, seeded on 10 cm2 plates and partly frozen when confluent. Single
clones were established using the limited dilution method. Cells were counted and
diluted to 1 cell/100 µl medium containing G418. 100 µl of cell suspension was added
per well of a 96-well-plate. After 5 days, 50 µl medium containing 3x G418 was added to
the wells. Formation of single cell patches was controlled by microscopy. After reaching
confluency, cells were gently transferred to 6-well-plates and T25 flasks. The receptor
expression level was checked using flow cytometry analysis. Clones of the different
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receptor variants with similar expression levels were chosen for further experiments. 
4.2.1.4 Isolation of HUVEC 
Primary human umbilical vein endothelial cells were freshly prepared from human
umbilical veins. For this purpose, 10 - 15 cm of umbilical vein were flushed with PBS to
avoid contamination with blood cells. Afterwards, the vein was filled with collagenase
type II solution (40 µg/ml in PBS) and incubated for 15 minutes at 37°C. Cells were then
flushed out of the vein with 50 ml PBS and centrifuged at 300xg at room temperature.
Cells were resuspended in supplemented HUVEC growth medium and grown on
collagen G-coated cell culture dishes (coating: 15 minutes with 40 µg/ml collagen G in
PBS). HUVEC were subcultured before reaching confluency for a maximum of 4
passages. 
4.2.1.5 Isolation of PBMCs 
Human peripheral blood mononuclear cells (PBMC) were isolated from citrated
(0.38%) venous blood of healthy volunteers by 1:1 dilution in PBS and subsequent
density gradient centrifugation on a Ficoll Hypaque layer (25 ml blood-PBS mixture on
25 ml Ficoll Hypaque) for 40 minutes at RT without brake. PBMC that accumulated in
the middle layer were carefully taken off and, after 2-fold washing with PBS, PBMC
were used for functional assays as decribed below. 
4.2.2 Cloning 
4.2.2.1 hCX3CR1 and its variants in pcDNA3.1 
Human CX3CR1 cDNA was previously amplified by Matthias Voss from human
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PBMC using the primers indicated in section 4.1.2 and cloned into pcDNA3.1+ using
XhoI and EcoRI as restriction sites generating hCX3CR1-pcDNA3.1+. Based on this
plasmid, the truncation variant of hCX3CR1 that lacks all intracellular serine-residues
was generated by using an antisense primer with inserted stop codon at serine residue
319 and subsequent restriction site for XhoI. cDNA was amplified, and the product was
purified using gelelectrophoresis and a gel extraction kit. cDNA for the other receptor
variants was generated by site-directed mutagenesis via ligation PCR. An upstream
fragment was amplified using the CX3CR1 sense primer and a specific antisense primer
for the hCX3CR1 variant. Additionally, a downstream fragment was generated with
antisense primer for CX3CR1 and sense primers carrying the desired mutations. The
upstream and downstream PCR products were phosphorylated separately using
polynucleotide kinase and ligated before a PCR with CX3CR1 sense and antisense
primers was performed. The cDNA for the different receptor variants was ligated into
TOPO cloning vector and positive clones were selected with blue-white screening.
Clones were then grown and DNA was purified. The product was subsequently ligated
into the expression vector pcDNA3.1+ using EcoRI and XhoI. All sequences were
confirmed by sequencing. All plasmids were amplified in large scale and frozen for
immediate use. Protocols for the different steps are given below. 
Human CXCR6 cDNA was previously generated by Alexander Schulte from human
PBMC using the primers indicated in section 4.1.2 and cloned into pcDNA3.1+ using
XhoI and EcoRI as restriction sites generating hCXCR6-pcDNA3.1+ [Ludwig et al.,
2005]. Based on this plasmid, the variants of hCXCR6 were generated by the same
strategy used for the CX3CR1 variants.
PCR. For the variants of human CXCR6 and CX3CR1, ligation-PCRs were
performed. Alteration of the DRY and NPX2-3Y motifs required two PCRs leading to an
upstream and a downstream fragment. DNA polymerase of Pyrococcus furiosus (Pfu
polymerase) was used due to its integrated proof reading function and the generation of
blunt end fragments. The following protocol was used: 
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1 µl forward primer 
1 µl reverse primer 10' 95°C initial denaturation
0.5 µl pfu polymerase 2' 95°C denaturation 
5 µl pfu buffer 35 cycles 30'' 60°C primer annealing 
2 µl dNTP 2' 72°C elongation 
1 µl plasmid 10' 72°C final elongation 
39.5 µl A.dest. 
Agarose gel electrophoresis. After PCR was performed, products were separated
using agarose gel electrophoresis. Therefore, samples were mixed with 2x loading dye,
loaded onto 1% or 2% agarose gels including ethidiumbromide in TAE buffer and
separated using 100 V. Afterwards, bands of the desired size were cut on an UV-light
table. As standard, 5 µl of GeneRuler kb DNA Ladder was used.
TAE buffer (50x)
242 g Tris
57.1 ml acetic acid
100 ml 0.5 M EDTA, pH 8.0
ad 1000 ml A.dest.
Gel extraction. For DNA gel-extraction, the NucleoSpin extract II kit was used
according to manufacturer’s instructions. Briefly, gel fragment was mixed with buffer at
0.5 mg/µl and bound onto a column. After washing off salt and impurities, DNA was
eluted in 50 µl H2O. 
Phosphorylation of PCR fragments. PCR fragments had to be phosphorylated for
ligation. The following mixture was prepared for each fragment: 
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10 µl 10 x ligation buffer 
1 µl PCR product 
→ 5' 70°C 
2 µl T4 polynucleotide kinase 
→ 30' 37°C 
Ligation of PCR fragments. Subsequently, both phosphorylated fragments were
ligated using T4 ligase in the following mixture: 
5 µl phosphorylated upstream fragment 
5 µl phosphorylated downstream fragment 
1 µl T4 DNA ligase 
→ 60' RT 
PCR of ligation product. Ligation products were then amplified using PCR
technique. In this case, high fidelity Taq polymerase was used due to its integrated proof
reading function and the generated A-overhang in products. This PCR protocol was also
used for the truncation mutant of the receptor. 
1 µl forward primer 
1 µl reverse primer 10' 95°C initial denaturation
0.5 µl high fidelity Taq polymerase 2' 95°C denaturation 
5 µl high fid. Taq (incl Mg2+) buffer 35 cycles 30'' 60°C primer annealing 
2 µl dNTP 2' 72°C elongation 
1 µl ligation or plasmid 10' 72°C final elongation 
39.5 µl A.dest. 
Subsequently, PCR products were separated using agarose gel electrophoresis and the
fragment at about 1 kb was cut and extracted. 
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TOPO TA cloning. For further amplification PCR products were cloned into TOPO
vector using the TOPO TA cloning kit according to manufacturer’s instructions.
Therefore, the following mixture was prepared: 
4 µl PCR product 
1 µl salt solution 
1 µl vector 
→ 10' RT 
This mixture was then used for heat-shock transformation. 
Heat-shock transformation. To transfer the plasmid containing the desired sequence
into bacteria, heat-shock transformation was used. E.coli TOP10 bacteria were incubated
with 1.5 µl of plasmid for 30 minutes on ice. For heat-shock, cells were incubated for 40
seconds at 42°C and then incubated for 5 minutes on ice. Cells were then mixed with 450
µl SOC medium (SOB medium supplemented with 20 mM glucose) and incubated for 1
hour at 37°C while shaking. 100 µl of cell suspension were spread on agar plates
containing ampicillin and X-gal for TOPO cloning and only ampicillin for pcDNA3.1+
cloning. Plates were incubated over night at 37°C. 
Clone selection. For TOPO cloning, colonies were selected via blue-white-screening.
White colonies represent positive clones that integrated the plasmid, whereas blue
colonies did not include the plasmid. For pcDNA3.1+ cloning, colonies were picked
randomly with a pipette tip and tested for transformation via colony PCR technique.
Picked clones were transferred into 5 ml LB medium and grown over night at 37°C. 
Colony PCR. Successful transformation was tested via PCR technique. As template
the pipette tip with the picked colony was dipped into the reaction mix. Following
protocol was used:
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0.5 µl forward primer 
0.5 µl reverse primer 10' 95°C initial denaturation
0.5 µl Taq polymerase 1' 95°C denaturation 
3 µl Taq (excl. Mg2+) buffer 30 cycles 30'' 63°C primer annealing 
5 µl Mg2+ 1' 72°C elongation 
1 µl dNTP 10' 72°C final elongation 
39.5 µl A.dest. 
Subsequently, the products were visualized using agarose gel electrophoresis.
MiniPrep. Amplified plasmids were purified using a plasmid DNA purification kit
according to manufacturer’s instruction. Briefly, cells were sedimented, lysed and DNA
and proteins were precipitated. DNA was then bound onto a silica column. After washing
off contaminants, plasmids were eluted in A.dest. 
Restriction. In order to express the gene product in mammalian cells, the cDNA was
transferred from the TOPO vector into the eukaryotic expression vector pcDNA3.1+.
Therefore, the desired sequence was cut out of the TOPO vector, and the pcDNA3.1+
vector was cut for linearization using the following mixture: 
1 µl EcoRI 
1 µl XhoI 
6 µl Tango Buffer 
1 µl plasmid (TOPO and pcDNA3.1+) 
21 µl A.dest. 
→ 3 h 37°C 
Subsequently, products were separated using agarose gel electrophoresis, and the
fragment at about 1 kb and the linearized pcDNA3.1+ vector were cut and extracted. 
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Ligation into pcDNA3.1+. For ligation of the DNA into pcDNA3.1+ with T4 ligase
the following protocol was used: 
10 µl insert 
1 µl plasmid 
1 µl T4 DNA ligase 
3 µl T4 DNA ligase buffer 
15 µl A.dest. 
→ over night 16°C 
The ligated plasmid was then transferred into E.coli using heat-shock transformation
as described above. 
4.2.2.2 Fractalkine-Fc fusion protein 
An expression vector for the fusion protein of human CX3CL1 and human IgG1-Fc-
fragment (hFc) was generated previously by Matthias Voss. cDNA coding for hFc was
inserted into pcDNA3.1 using EcoRI and XhoI. Subsequently, a cDNA fragment for the
ectodomain of human CX3CL1 was generated by PCR using sense and antisense primers
as indicated in table 4.1.2, and then inserted into pcDNA3.1-Fc using HindIII and EcoRI.
All sequences were confirmed by sequencing. 
4.2.3 Molecular biology and proteinbiochemistry
4.2.3.1 Analysis of surface expression 
Cells were analyzed for surface expression of chemokine receptors or transmembrane
chemokines by staining with appropriate antibodies (see table 4.1.4). Cells were
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harvested, washed with PBS, and resuspended to 1x106 cells/ml in PBS with 0.2% BSA.
Cells were then incubated with antibody solution at the indicated final concentration and
in a final volume of 25 µl. For directly fluorescently labeled antibodies, cells were
stained for 30 minutes on ice in the dark, washed twice with 250 µl PBS with 0.2% BSA
to remove excess antibody, and resuspended in 100 µl PBS with 0.2% BSA. For
unlabeled antibodies, cells were incubated with first antibody on ice for 30 minutes, after
washing they were incubated with the fluorescently labeled detection antibody against
the first antibody on ice in the dark for another 30 minutes and washed afterwards. For
immediate measurements, no fixation was used, and cells were resuspended in PBS with
0.2% BSA, otherwise cells were resuspended in 4% PFA in PBS with 0.2% BSA and
kept cold in the dark. The fluorescence signal was then analyzed by flow cytometry. 
PBS (phosphate buffered saline)
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4
2 mM KH2PO4 
in A.dest.
4.2.3.2 ELISA
For ELISA (enzyme-linked immunosorbent assay) detection of soluble CX3CL1,
MaxiSorp flat-bottom 96-well plates were coated over night with coating antibody at a
final concentration of 4 µg/ml in PBS at room temperature. Plates were then washed 3
times with washing buffer (PBS with 0.05% Tween) and blocked for 2 hours with
blocking buffer (PBS with 0.05% Tween and 2% BSA) at room temperature. Samples
and standard were added after washing and incubated for 1 hour at room temperature.
After washing 3 times with washing buffer, anti-CX3CL1-biotin antibody in a final
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concentration of 0.3 µg/ml in blocking buffer was added and incubated for 1 hour at
room temperature. After washing with washing buffer, Streptavidin-POD was added in a
1:5000 dilution in blocking buffer, and incubated for 1 hour at room temperature. After
washing 4 times with washing buffer, substrate solution was added, incubated for 10-20
minutes and the reaction was stopped using 100 µl 1M H2SO4. The signal was then
measured in a plate reader at a wavelength of 450 nm with a reference wavelength of 550
nm.
4.2.4 Functional assays 
4.2.4.1 Ligand binding 
For CX3CL1 binding experiments, cells were harvested, washed with PBS and
resuspended to 2x106 cells/ml in PBS with 0.2% BSA. Cells were then incubated for 1
hour on ice with a 1:10 dilution of the supernatant of HEK293 cells transfected to
express soluble CX3CL1 that was fused to the Fc-part of human IgG1. After washing off
excess CX3CL1-Fc twice with 250 µl PBS with 0.2% BSA, the Fc-part was detected
using a fluorescently labeled α-Fc-antibody in a final volume of 25 µl. Cells were
incubated with the antibody for 30 minutes on ice in the dark. After washing off excess
antibody twice with 250 µl PBS with 0.2% BSA, cells were resuspended in 100 µl PBS
with 0.2% BSA and the fluorescence signal was measured by flow cytometry. 
For CXCL16 binding experiments, cells were harvested, washed with PBS and
resuspended to 2x106 cells/ml in PBS with 0.2% BSA. Cells were then incubated for 1
hour on ice with 100 ng/ml recombinant 6xHis-tagged CXCL16 in the absence or
presence of 1 µg/ml recombinant untagged CXCL16. After washing off excess CXCL16
twice with 250 µl PBS with 0.2% BSA, the 6xHis-tag was detected with a mouse
anti-6xHis-antibody for 30 minutes on ice in a final volume of 25 µl. After two washing
steps with 250 µl PBS with 0.2% BSA, cells were incubated with a goat anti-mouse PE-
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labeled antibody for 30 minutes on ice in the dark. After washing off excess antibody
twice with 250 µl PBS with 0.2% BSA, cells were resuspended in 100 µl PBS with 0.2%
BSA and the fluorescence signal was measured by flow cytometry. 
4.2.4.2 Ligand uptake 
For ligand uptake experiments, cells were harvested and resuspended to 2x106 cells/ml
in PBS with 0.2% BSA. Prior to CX3CL1-treatment, cells were left on ice for 30 minutes
with or without 0.2% NaN3. Cells were then incubated with 10 nM AlexaFluor647-
labeled CX3CL1 chemokine domain at 4°C or 37°C for 30 minutes in a final volume of
25 µl. Cells were washed twice with 250 µl ice-cold PBS with 0.2% BSA or PBS with
0.2% BSA containing 0.2% NaN3, resuspended with ice-cold PBS with 0.2% BSA or
PBS with 0.2% BSA containing 0.2% NaN3 and kept on ice to avoid further ligand
uptake. The fluorescence signal was measured by flow cytometry. 
4.2.4.3 Intracellular calcium transients 
Cells were harvested, resuspended in PBS to 2x106 cells/ml, and loaded with 4 µg/ml
of the calcium-indicator Fluo-3-AM for 30 minutes at 37°C. After two-fold washing with
calcium assay buffer, cells were resuspended and kept in calcium assay buffer
supplemented with 1% FCS. Before measurement, 2.5x106 cells were resuspended in 1.5
ml assay buffer containing no calcium, but 0.3 mM EDTA. Cells were incubated in a
plastic cuvette at 37°C under constant stirring and Fluo-3 fluorescence was continuously
monitored at excitation and emission wavelengths of 490 and 526 nm, respectively, using
a fluorescence spectrophotometer. After 100 seconds, cells were stimulated with 10 nM
CX3CL1 or CXCL16 chemokine domain, and the fluorescence signal was recorded for
200 seconds. Finally, loading of cells with fluorescent dye was controlled by addition of
calcium (1.6 mM) and digitonin (125 µg/ml), leading to maximal signal by complex
formation of Fluo-3 with calcium, and finally by addition of EGTA (15 mM) for
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dissolving the complex. 
Calcium Assay Buffer 
138 mM NaCl 
6 mM KCl 
1 mM MgCl2 
5.5 mM D-Glucose 
20 mM HEPES 
1.6 mM CaCl2 
in A.dest.
pH 7.4 
4.2.4.4 Adhesion under static conditions 
For adhesion under static conditions, cells expressing the ligand (HUVEC or ECV304)
were seeded onto 24-well-plates and were cultured to full confluency as confirmed by
microscopy. HUVEC were pretreated with 10 ng/ml TNFα and 10 ng/ml IFNγ 16 hours
prior to the experiment to stimulate chemokine expression. L1.2 cells or PBMC were
harvested and stained with 10 µM CalceinAM in PBS for 15 minutes at 37°C in the dark,
and after washing off excess dye, 5x105 cells in PBS were centrifuged with 300xg for 3
minutes onto the chemokine expressing HUVEC or ECV304 cell layer. The fluorescence
signal of adherent cells was measured in a fluorescence plate reader after each of 12
washing steps with PBS at an excitation wavelength of 480 nm and an emission
wavelength of 550 nm. 
The number of adherent cells is given as adhesion index (AI) that was determined by
dividing the number of adherent cells on ligand-expressing cells by random adhesion of
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cells on a cell layer that does not express the ligand.
4.2.4.5 Adhesion under flow conditions 
For adhesion under flow conditions, ECV304 cells or HUVEC were seeded onto a
flow adhesion chamber and were cultured to full confluency. HUVEC were stimulated
with 10 ng/ml IFNγ and TNFα 16 hours prior to assay to induce CX3CL1 expression.
HEK293 cells or PBMC were stained with 10 µM CalceinAM for 15 minutes at 37°C in
the dark, washed to remove of excess dye and resuspended in flow adhesion buffer to
5x105 cells/ml. The flow adhesion chamber containing the ECV304 or HUVEC cell layer
was then connected to a syringe pump and inserted into a temperature controled
incubation chamber culture on the stage of an inverted microscope. After washing the
cell layer with warm flow adhesion buffer for 3 minutes, it was perfused by a suspension
of calcein-labeled cells with a shear stress rate of 2 dyne for 1 minute. Thereafter, 8
subsequent pictures were taken, and the number of adherent cells was determined. 
Flow Adhesion Assay Buffer 
10% HBSS 
1% HEPES 
1% BSA 
in A.dest. 
The number of adherent cells is given as adhesion index (AI) that was determined by
dividing the number of adherent cells on ligand-expressing cells by random adhesion of
cells on a cell layer that does not express the ligand.
4.2.4.6 Chemotaxis 
Stably transfected L1.2 cells or PBMC were harvested, washed twice with RPMI1640
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with 0.2% BSA, and resuspended at 2x106 cells/ml in RPMI1640 with 0.2% BSA. The
lower wells of a modified 48-well Boyden chamber were filled with 29.5 µl RPMI1640
with 0.2% BSA with or without the indicated concentrations of CX3CL1 or CXCL16
chemokine domain, covered with a polycarbonate membrane with 8 µm pores, and 30 µl
of cell suspension was added to the upper wells. After incubation of 2 hours at 37°C,
migrated cells were counted using a hemacytometer. 
The number of migrated cells is given as migration index (MI) that was determined by
dividing the number of migrated cells treated with a stimulus by random migration of
unstimulated cells.
4.2.4.7 Transmigration 
ECV304 cells or HUVEC were seeded on transwell filters with 8 µm pores and grown
to confluency. L1.2 cells or PBMC were harvested, washed twice with with 0.2% BSA,
and resuspended to 2x106 cells/ml in RPMI1640 with 0.2% BSA. 24-well culture plates
were filled with 600 µl/well RPMI1640 with 0.2% BSA with or without the indicated
concentrations of CX3CL1 or CXCL16 chemokine domain. Transwell inserts containing
the HUVEC or ECV304 cell layer were then placed into the wells and filled with 100 µl
of L1.2 or PBMC cell suspension. After incubation for 2 hours at 37°C, transmigrated
cells were counted using a hemacytometer. 
The number of transmigrated cells is given as transmigration index (TI) that was
determined by dividing the number of transmigrated cells treated with a stimulus by
random transmigration of unstimulated cells.
4.2.4.8 Pseudopod formation 
Wt- or CX3CL1-ECV304 cells were seeded on glass bottom dishes and grown to
confluency. L1.2 cells were harvested, washed twice with RPMI1640 with 0.2% BSA,
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resuspended to 2x105 cells/ml in RPMI1640 with 0.2% BSA and placed on the ECV304-
cell layer in the prewarmed chamber at 37°C. Time-lapse videos were captured using a
LSM 7 Duo Microscope for 5 minutes, and 100 cells per condition were analyzed for
pseudopod formation. Evaluation for pseudopod formation defined as temporal
protrusions from the cell body with a minimal length of 0.5 µm was done in a blinded
fashion. 
4.2.5 Statistical analysis
Data were statistically analyzed by using the one-way ANOVA with posthoc
Bonferroni’s Multiple Comparison t-tests using GraphPadPrism software (GraphPad
Prism 5.01, GraphPad Software, San Diego, CA). In case of heteroscedasticity (Bartlett
test), data were log transformed prior to analysis. The data in Figures 23 and 25 were
analyzed by the Mixed Model procedure in SAS 9.1 (SAS Institute, Cary, NC). Multiple
comparisons were corrected by the Bonferroni-Holm procedure. In the figures only those
comparisons with interest to the main hypotheses are indicated. 
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5 Results 
5.1 CX3CR1-CX3CL1 interaction 
In order to characterize the interaction between CX3CR1 and CX3CL1, I started by
determining whether the interaction of fractalkine and CX3CR1 results in firm adhesion
and (trans-)migration of PBMC. Since CX3CR1 is described to be constitutively
expressed on monocytes and T-cell populations, peripheral blood mononuclear cells
from blood of healthy donors were isolated, and tested for the expression of CX3CR1
using a PE-labeled antibody in flow cytometry. I found that the level of expression
varied depending on donor and cell type. As expected, the highest expression of
CX3CR1 could be seen on monocytes, and lower expression was found on a
subpopulation of T-cells (Figure 7). For further experiments PBMC from donors with a
strong expression of CX3CR1 were used. 
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Figure 7: CX3CR1 is expressed on PBMC. Freshly isolated blood mononuclear
cells of healthy donors were probed for their expression of CX3CR1 using a PE-la-
beled anti-hCX3CR1 antibody. Cells were gated for monocytes by sideward and
forward scatter dotplot. The grey shaded curve represents the isotype control, the
black unshaded curve represents hCX3CR1 expression. Data are shown as a repre-
sentative histogram. 
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A fundamental step in leukocyte recruitment is the firm adhesion on the endothelium
lining the blood vessel. Therefore, freshly isolated PBMC were tested for their ability to
mediate adhesion under flow conditions. For this purpose, wt-ECV304 or CX3CL1-
ECV304 were grown to confluency to form a stable cell layer to which PBMC could
adhere. Using a syringe pump, freshly isolated PBMC were directed over this cell layer
for 1 minute with a shear force stress similar to that of the post-capillary system (2 dyne/
cm2), and the adherent PBMC were counted. 8.3 times more PBMC adhered on a
CX3CL1-expressing ECV304 cell layer compared to a wt-ECV304 cell layer (Figure 8),
indicating that CX3CL1 may function as adhesion molecule as was shown earlier. 
!"#$%&'() %*'%+,#$%&'()
(-(
.-/
/-(
0-/
,(-( 1
23
45
67
89
:;9
35
<
Figure 8: PBMC adhere to a CX3CL1 expressing cell layer under flow condi-
tions. Freshly prepared PBMC were assayed for adhesion under flow conditions on
a wt-ECV304 or a CX3CL1-ECV304 cell layer. PBMC were stained with Cal-
ceinAM for 15 minutes. Excess dye was removed by washing, and cells were sus-
pended to a concentration of 5x105 cells/ml in warmed flow adhesion buffer. The
ECV304 cell layer was washed with warmed flow adhesion buffer, and then PBMC
were directed onto the layer under a steady shear stress rate of 2 dyne/cm2 under a
fluorescence microscope. Adherent cells were counted after 1 minute. Data are
shown as mean ± SD of three independent experiments. *, p<0.05 versus the un-
transfected control. 
Since leukocyte adhesion is usually followed by transmigration through endothelial
cells, I tested PBMC for their ability to migrate towards CX3CL1. Freshly prepared
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PBMC were assayed for chemotaxis in response to soluble CX3CL1 chemokine domain
(1 - 100 nM) in a modified 48-well Boyden chamber setting. 2.2 times more PBMC
migrated into the lower well when 10 nM CX3CL1 was present in the lower well.
Chemotaxis towards CX3CL1 was dose-dependent and showed the characteristic bell
shaped curve reported for chemokines, peaking at 10 nM soluble CX3CL1 chemokine
domain (Figure 9). Based on this curve, all further experiments were performed with 10
nM soluble CX3CL1 chemokine domain. 
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Figure 9: PBMC chemotactically migrate towards CX3CL1. PBMC were seed-
ed onto a polycarbonate membrane with 8 µm pores in a modified Boyden chamber
setting. 1 - 100 nM soluble CX3CL1 chemokine domain were used to excite
chemotaxis for 2 hours at 37°C. Subsequently, migrated cells were counted. Data
are shown as mean ± SD of three independent experiments. *, p<0.05 versus ran-
dom migration without stimulus. 
Chemotaxis describes the process of cell movement through a membrane instead of
the interaction of different cell types with each other and subsequent movement through
a confluent cell layer (transmigration). To study the latter process, the capability of
freshly isolated PBMC to transmigrate through a cell layer expressing CX3CL1 was
tested. Transmigration was studied in the absence or presence of soluble CX3CL1 that
was added to the lower compartment of a transwell insert. As expected, transmigration of
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PBMC was 1.9 fold increased when soluble CX3CL1 was used as a chemoattractant.
Transmigration was also increased (Transmigration Index (TI) = 1.7) when
transmembrane CX3CL1 was expressed on the ECV304 cell layer. However,
simultaneous presence of transmembrane and soluble CX3CL1 did not further enhance
transmigration (TI = 1.8) (Figure 10). 
wt-ECV304 CX3CL1-ECV304
0.0
0.5
1.0
1.5
2.0
2.5
none
10nM CX3CL1
Tr
an
sm
ig
ra
tio
n 
In
de
x *
Figure 10: PBMC chemotactically transmigrate in response to CX3CL1. Fresh-
ly prepared PBMC were assayed for transmigration through wt- or CX3CL1-
ECV304 cell layers cultured in transwell inserts. After washing, 2x105 PBMC were
seeded onto the confluent cell layer for 2 hours at 37°C. Subsequently, transmigrat-
ed cells were counted. Data are shown as mean ± SD of three independent experi-
ments. *, p<0.05 versus the migration without the addition of stimulus. 
In order to use primary endothelial cells as cell layers in transmigration assays,
HUVEC were isolated from human umbilical veins. Under normal cell culture
conditions, they do not express CX3CL1 endogenously. When these cells were
stimulated with IFNγ and TNFα for 16 hours, they expressed CX3CL1 in considerable
amounts, as was shown earlier and by FACS analysis (Figure 11) [Ludwig et al., 2002].
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Figure 11: Stimulated HUVEC express CX3CL1. Primary human umbilical vein
endothelial cells were stimulated with IFNγ and TNFα (both 10 ng/ml) for 16 hours
or left untreated, and were subsequently stained for CX3CL1 surface expression us-
ing an anti-CX3CL1 antibody. The grey shaded curve represents the unstimulated
control, the black unshaded curve represents hCX3CL1 expression after IFNγ and
TNFα treatment. Data are shown as a representative histogram. 
To analyze transmigration in a more physiologic setting, I next used HUVEC as a cell
layer for transmigration. Transmigration of PBMC was considerably increased (TI = 3)
(Figure 12) when these cells were stimulated with IFNγ and TNFα to express
endogenous CX3CL1. This transmigration was almost completely suppressed by
pretreatment of the HUVEC layer with a neutralizing antibody to CX3CL1. Since firm
adhesion occurs prior to the transmigration process, adhesion molecules like ICAM-1 or
VCAM-1 might also play an important role in transmigration of PBMC towards
CX3CL1. Additionally, treatment of HUVEC with IFNγ and TNFα might not only
increase CX3CL1 expression, but also that of adhesion molecules. To find out whether
CX3CL1 is sufficient to promote the transmigration process, neutralizing antibodies to
ICAM-1 and VCAM-1 were used. The inhibition of VCAM-1 and ICAM-1 was as
efficient as that obtained with neutralizing antibodies to CX3CL1 (TI = VCAM-1: 1.4;
ICAM-1: 1.3; CX3CL1: 0.9), indicating that CX3CL1 is necessary but not sufficient to
induce transmigration. 
5 Results
52
!"#$%&' ()$*+,-.,/0 ()$*+!,12+0 ()$*+3,12+0
4
0
5
.
6
7
8)$9'($':
!;<!=>=?<;"
@
?9
()
"A
*B
9(
$*#
)=
!)
:'
C
Figure 12: Neutralizing of CX3CL1, ICAM-1 and VCAM-1 prevents PBMC
transmigration. HUVEC were left unstimulated or were stimulated with IFNγ and
TNFα (both 10 ng/ml) for 16 hours and subsequently treated with neutralizing anti-
bodies against CX3CL1, ICAM-1 and VCAM-1 or isotype control for 1 hour. After
washing, 2x105 PBMC were seeded onto the cell layer for 2 hours at 37°C. Subse-
quently, transmigrated cells were counted. Data are shown as mean ± SD of three
independent experiments. *, p<0.05 versus the untreated control. 
It is known that chemokines are internalized upon binding to their receptor. This
process is mediated by β-arrestin and involves the formation of clathrin-coated vesicles
(reviewed in [Moore et al., 2007]. Dynamins are essential for their formation since they
are needed in the transition from a fully formed pit to a pinched-off vesicle. Dynasore is
a small molecule GTPase inhibitor that targets dynamins and therefore blocks dynamin-
dependent endocytosis [Macia et al., 2006]. To address the question, whether
internalization of the ligand-receptor complex also plays a critical role in the
extravasation process, transmigration of PBMC after pretreatment with dynasore was
analyzed. When PBMC were pretreated with dynasore, they did not transmigrate through
a wt-ECV304 cell layer towards soluble CX3CL1 chemokine domain or due to the
interaction with transmembrane CX3CL1 on ECV304 cells (TI = 1.06, TI = 0.95, control
= 1.01) (Figure 13). 
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Figure 13: Dynasore prevents transmigration of PBMC. PBMC were pretreated
for 30 minutes with 100 µM dynasore or left untreated. After washing, cells were
assayed for transmigration through wt- or CX3CL1- ECV304 cell layers cultured in
transwell inserts. 2x105 PBMC were seeded onto the confluent cell layer for 2 hours
at 37°C. Subsequently, transmigrated cells were counted. Data are shown as mean ±
SD of three independent experiments. *, p<0.05 versus the untransfected control. 
The data demonstrate that transmembrane CX3CL1 that is expressed on the cell
surface of endothelial cells not only functions as an adhesion molecule for CX3CR1-
expressing blood mononuclear cells, but can also mediate transmigration through an
endothelial cell layer. 
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5.2 Model system for CX3CR1-CX3CL1 function 
In order to establish a model system for a more detailed molecular analysis of the
CX3CR1-CX3CL1 system in adhesion and transmigration, two different cell lines were
used that were transfected to express CX3CR1. HEK293 cells were originally derived
from human embryonic kidney cells grown in tissue culture and have an epithelial
morphology. They were already used in a vast variety of receptor studies. Since HEK293
cells did not migrate in our setting, the murine pre-B-cell line L1.2 (also named 300-19)
was used for chemotaxis experiments. Both cell lines do not express CX3CR1
endogenously. 
Initial chemotaxis experiments confirmed that CX3CL1 promotes migration of
CX3CR1-transfected L1.2 cells towards soluble CX3CL1 chemokine domain as was
already shown for PBMC (Figure 14). The migration efficiency was comparable to that
obtained for PBMC (Migration Index (MI) = 2.2), with a 2.7 fold increase of migrated
cells. Moreover, HEK293 cells were transfected to express CX3CR1 and assayed for
their ability to adhere to a CX3CL1-expressing ECV304 cell layer, to show that
CX3CR1 mediated adhesion to CX3CL1 under static conditions (Adhesion Index (AI) =
7.4) (Figure 14). 
Next, CX3CR1-expressing L1.2 cells were assayed for transmigration through a wt- or
CX3CL1-ECV304 cell layer in the absence or presence of soluble CX3CL1 in the lower
compartment of the transwell chamber. Both soluble and transmembrane CX3CL1
induced transmigration of CX3CR1-L1.2 cells (TI = 1.7 and 1.9, respectively), but not of
wt-L1.2 cells (Figure 15). Simultaneous presence of transmembrane and soluble
CX3CL1 did not further enhance transmigration (TI = 1.9), as was previously seen for
PBMC. 
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Figure 14: L1.2 cells migrate towards CX3CL1 and HEK293 cells adhere to
CX3CL1. (left) L1.2 cells were seeded onto a polycarbonate membrane with 8 µm
pores in a modified Boyden chamber setting. 10 nM soluble fractalkine chemokine
domain were used to excite chemotaxis for 2 hours at 37°C. Subsequently, migrated
cells were counted. (right) Fluorescently labeled wild type or CX3CR1-expressing
HEK293 cells were seeded onto wild type ECV304 cells or ECV304 cells express-
ing transmembrane CX3CL1, and the fluorescence signal of the adherent HEK293
cells was determined after washing. Data are shown as mean ± SD of three inde-
pendent experiments. *, p<0.05 versus the controls (random migration of untrans-
fected cells and adhesion of untransfected cells, respectively). 
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Figure 15: L1.2 cells transmigrate through an ECV304 cell layer. Wt- and
CX3CR1-L1.2 were investigated for transmigration across wt- or CX3CL1-
ECV304 cells cultured in trans-well inserts. After washing, 2x105 L1.2 cells were
seeded onto the confluent cell layer for 2 hours at 37°C in the absence or presence
of additional 10 nM CX3CL1 chemokine domain in the lower compartment. Subse-
quently, transmigrated cells were counted. Data are shown as mean ± SD of three
independent experiments. *, p<0.05 versus the random transmigration of untrans-
fected cells without addition of stimulus control. 
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These studies are well in line with the observations made with primary PBMC and
suggest that the transfected cell lines may be used to investigate chemokine-mediated
cell recruitment. In the next step, the transmigration process was further analyzed with
regard to CX3CL1 expression, signaling and internalization. 
I then used HUVEC as a cell layer for transmigration of L1.2 cells. When these cells
were stimulated with IFNγ and TNFα to express endogenous CX3CL1, CX3CR1-L1.2
cells but not wt-L1.2 cells transmigrated through the HUVEC layer (TI = 3.1) (Figure
16). 
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Figure 16: L1.2 cells transmigrate through a HUVEC cell layer. HUVEC were
stimulated with IFNγ and TNFα (both 10 ng/ml) for 16 hours or left untreated. Sub-
sequently, wt- and CX3CR1-L1.2 cells were assayed for transmigration across the
HUVEC layer. After washing, 2x105 L1.2 cells were seeded onto the confluent cell
layer for 2 hours at 37°C. Subsequently, transmigrated cells were counted. Data are
shown as mean ± SD of three independent experiments. *, p<0.05 versus the unsti-
mulated, untransfected control. 
In the previously shown transmigration assay, HUVEC were stimulated to express
CX3CL1 and washed before the assay was performed. To find out whether sufficient
amounts of soluble CX3CL1 to induce transmigration were produced during the assay,
the medium in both compartments of the transwell system was tested in an ELISA for
soluble CX3CL1. As shown in Figure 17, after incubation with pro-inflammatory
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cytokines over night soluble CX3CL1 was produced by HUVEC in an amount that was
shown to promote chemotaxis of PBMC and CX3CR1-L1.2 cells (Figures 9 and 14). In
contrast, 2 hours were not sufficient to produce enough soluble CX3CL1 to mediate
efficient chemotaxis, as there were no detectable differences between stimulated and
unstimulated cells.
!"# $"!!"% !"# $"!!"%
&'&
&'(
)'&
)'(
*'&
*'(
+"+,
-./!0102/."
)30405!6%789!6"+ *0409:!,;0<9546+=
>
>
+=
?%
805
"8
7$
8,
0@
AB
@
C)
Figure 17: HUVEC produce CX3CL1 after stimulation with cytokines. HU-
VEC were stimulated with IFNγ and TNFα (both 10 ng/ml) for 16 hours or left un-
treated. Medium was collected, cells were washed three times and new medium
was given. Cells were left untreated for 2 hours at 37°C and afterwards medium
was collected and subjected to an ELISA for CX3CL1. Data are shown as mean ±
SD of three independent experiments. *, p<0.05 versus the unstimulated control. 
Since CX3CL1 is expressed as transmembrane as well as soluble form by endothelial
cells, it is not clear, which form is most important for the transmigration process. The
previous experiment provides an indication that transmembrane CX3CL1 is sufficient to
promote transmigration of CX3CR1-expressing cells. To elucidate the role of
transmembrane CX3CL1, CX3CL1-ECV304 cells were pretreated with a neutralizing
antibody against CX3CL1 for 15 minutes prior to the transmigration assay. Pretreatment
of CX3CL1-ECV304 cells with a neutralizing antibody against CX3CL1 that was added
to the upper compartment of the transwell system (apical site of ECV304 cells) clearly
reduced cell transmigration (TI = 3.3 to TI = 1.5), whereas addition of the antibody to the
5 Results
58
lower compartment (basolateral site) did not suppress cell transmigration (TI = 3.1 to TI
= 2.4) (Figure 18). Simultaneous application of the neutralizing antibody to the upper
and lower compartment did not further decrease transmigration (TI = 3.2 to TI = 1.8).
These data indicate that transmembrane CX3CL1 is crucial for CX3CL1-dependent
transmigration. 
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Figure 18: CX3CL1 inhibition influences transmigration. The neutralizing mon-
oclonal antibody to CX3CL1 or isotype control (10 µg/ml) was added to the lower
or the upper compartment of transwell inserts containing wt- or CX3CL1-ECV304
cells. After 15 minutes, the antibody was removed and the cells were investigated
for transmigration of CX3CR1-L1.2 cells. Data are shown as mean ± SD of three
independent experiments. *, p<0.05 versus the untreated, transfected control.
It has been previously demonstrated that pretreatment with soluble CX3CL1 blocks
chemotaxis as well as cell adhesion via CX3CL1, whereas pretreatment with the Gi-
protein inhibitor pertussis toxin (PTX) selectively blocks chemotaxis, but not adhesion
[Fong et al., 1998; Lucas et al., 2003]. Pertussis toxin is an exotoxin with six subunits
released by Bordetella pertussis. Once active, it catalyzes the ADP-ribosylation of the α-
subunit of the Gi-protein and therefore prevents the G-proteins from interacting with G-
protein coupled receptors on the cell membrane. To characterize CX3CL1-mediated
transmigration, CX3CR1-L1.2 cells were pretreated with soluble CX3CL1 or with PTX,
before transmigration through a ECV304 cell layer was assayed. In the transmigration
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assays using CX3CL1-ECV304 cells as substrate, pretreatment with soluble CX3CL1 or
with PTX efficiently suppressed transmigration of CX3CR1-L1.2 cells (TI = 0.85 and
1.14, respectively; control = 2.2) (Figure 19). 
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Figure 19: PTX treatment influences transmigration. Wt- and CX3CR1-L1.2
cells were pretreated for 30 minutes with soluble CX3CL1 (10 nM) or 2 hours with
PTX (100 ng/ml) and subsequently assayed for transmigration across wt- or
CX3CL1-ECV304 cells. After washing, 2x105 L1.2 cells were seeded onto the con-
fluent cell layer for 2 hours at 37°C. Subsequently, transmigrated cells were count-
ed. Data are shown as mean ± SD of three independent experiments. *, p<0.05 ver-
sus the transfected, untreated control. 
To address the question, whether internalization of the ligand-receptor complex also
plays a critical role in the extravasation process of L1.2 cells, chemotaxis of L1.2 cells
after pretreatment with dynasore was analyzed. When L1.2 cells were pretreated with
dynasore they did not migrate towards soluble CX3CL1 chemokine domain (MI = 1.2,
control = 2.8) (Figure 20). 
Taken together, the data indicate that HEK293 cells as well as L1.2 cells transfected
with CX3CR1 are an appropriate model system for the analysis of molecular
determinants of CX3CR1 function with regard to CX3CR1-CX3CL1 interaction.
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Furthermore, transmembrane fractalkine seems to be crucial for CX3CL1-mediated
transmigration, whereas pretreatment of CX3CR1 expressing cells with soluble CX3CL1
inhibits transmigration. Both, the inhibition of G-protein/GPCR interaction and
inhibition of clathrin-coated vesicle formation led to a dramatically reduced chemotaxis
of CX3CR1-L1.2 cells towards CX3CL1. This data indicate that signaling as well as
internalization are essential for transmigration. 
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Figure 20: Pretreatment with dynasore prevents L1.2 cell chemotaxis. Wt- and
CX3CR1-L1.2 cells were pretreated for 30 minutes with 100 µM dynasore or left
untreated. After washing, cells were assayed for chemotaxis towards 100 ng/ml
CX3CL1 chemokine domain in a modified Boyden chamber setting for 2 hours at
37°C. Subsequently, migrated cells were counted. Data are shown as mean ± SD of
three independent experiments. *, p<0.05 versus the untreated, transfected control. 
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5.3 Molecular analysis of CX3CR1-CX3CL1 function 
To analyze the molecular prerequisites for CX3CL1-mediated adhesion and trans-
migration, the subsequent experiments concentrated on the receptor and addressed
conserved structures in the GPCR superfamily. Analysis showed that there are several
highly conserved motifs known to be important for GPCR signaling (Figure 21). The
aspartate-arginine-tyrosine (DRY) sequence in the second intracellular loop is required
for activation of Gi-proteins, whereas the NPX2-3Y motif located in the seventh
transmembrane region of most GPCR contributes to ligand binding, activation and
internalization of the receptor. 
Rhodopsin ALWSLVVLAI ERY VVVCKPMSNF ... AFFAKSAAIY NPVIY IMMNKQFRNC
CX3CR1 SIFFITVISI DRY LAIVLAANSM ... ETVAFSHCCL NPLIY AFAGEKFRRY
CXCR1 GILLLACISV DRY LAIVHATRTL ... EILGILHSCL NPLIY AFIGQKFRHG
CCR5 GIFFIILLTI DRY LAVVHAVFAL ... ETLGMTHCCI NPIIY AFVGEKFRNY
GnRHR PAFMMVVISL DRS LAITRPLALK ... FLFAFLNPCF DPLIY GYFSL 
CHRM1 SVMNLLLISF DRY FSVTRPLSYR 
ADRB1 SIETLCVIAL DRY LAITSPFRYQ ... NWLGYANSAF NPIIY CRSPDFRKAF
CXCR6 SMLILTCITV DRF IVVVKATKAY ... EAIAYLRACL NPVLY AFVSLKFRKN
Figure 21: Alignment of conserved motifs in GPCR superfamily. Different
members of class A or rhodopsin-like GPCR were aligned to show two important
conserved motifs in the GPCR superfamily. The DRY motif is located in the sec-
ond intracellular loop and always shows the characteristic arginine-residue, where-
as the aspartate-residue is sometimes changed to be glutamic acid. The tyrosine
residue is unfrequently altered to either serine or phenylalanine. The NPX2-3Y mo-
tif is located in the seventh transmembrane domain. The proline and the tyrosine
residues are seldom found to be changed, whereas the asparagine residue some-
times is altered to aspartate. The two or three unspecified amino acids are in most
cases leucine, isoleucine or valine. Abbreviations and Uniprot.org Accession num-
bers: Rhodopsin: P30968, CX3CR1: P49238, CXCR1: P25024, CCR5: P51681,
GnRHR: Gonadotropin-releasing hormone receptor, P30968, CHRM1: Muscarinic
acetylcholine receptor M1, P11229, ADRB1: Beta-1 adrenergic receptor, P08588,
CXCR6: O00574. 
Additionally, GPCR typically carry several serine residues within the intracellular C-
terminal region, which can become phosphorylated by G-protein-coupled receptor
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kinases and mediate interaction with β-arrestins, internalization via clathrin-coated
vesicles and subsequent desensitization of the receptor towards its ligand. The typical
DRY sequence, the NPX2-3Y motif and several C-terminal Ser-residues are also found
within CX3CR1 and very likely play a role in CX3CR1 signaling and function. To
analyze CX3CR1 function on molecular basis, CX3CR1 variants with altered conserved
motifs were constructed. I changed the DRY motif into DNY (R127N), the NPX2-3Y
motif into APX2-3Y (N289A) and NPX2-3A (Y293A), and truncated the intracellular
stalk at S319 (S319X) to remove all intracellular serine-residues. In Figure 22 all
locations for changes are shown. 
Figure 22: Overview of introduced changes in CX3CR1. CX3CR1 carries a
number of conserved sequences, which can be found throughout GPCR superfami-
ly, including a DRY motif in the second intracellular loop, a NPX2-3Y motif in the
seventh transmembrane domain and several serine residues at the C-terminus. To
alter these motifs, CX3CR1 was mutated at the indicated sites. R127 in the second
intracellular loop was mutated to asparagine (R127N), N289 and Y293 in the sev-
enth transmembrane domain were changed into alanine (N289A and Y293A, re-
spectively), and the intracellular C-terminus was truncated before S319 (S319X).
Locations for changes are indicated with filled circles. 
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The cDNA for CX3CR1 variants was constructed using two-fragment ligation (for
R127N, N289A and Y293A) or a simple PCR strategy (for S319X) and cloned into
pcDNA3.1+ expression vector. All constructs were successfully cloned and confirmed by
sequencing. To determine whether the CX3CR1 variants could be expressed, HEK293
cells were transiently transfected and tested for expression of CX3CR1 using flow
cytometry. As shown in Figure 23, all constructed variants could be readily detected on
the cell surface of HEK293 cells 2 days after transfection, all expressed with similar
intensity. To examine whether the transfected receptor variants bind CX3CL1, cells were
incubated with CX3CL1 that was fused to the Fc-part of human IgG1. This construct was
then detected by flow cytometry using an anti-Fc-antibody (Figure 23). Ligand binding
was still detectable for the R127N and S319X variants, but absent in the N289A and
Y293A variants. Since ligand binding is the crucial step for mediation of function, I
decided to concentrate further functional characterization on the R127N and S319X
mutations. 
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Figure 23: Expression and binding of CX3CR1 variants. Expression of the re-
ceptor variants was controlled by flow cytometry using PE-conjugated rat anti-
CX3CR1 antibody. Ligand binding was analyzed by flow cytometry using a recom-
binant CX3CL1-Fc construct as a ligand. Receptor expression and ligand binding
were measured as the mean fluorescence intensity increase compared to control.
After logarithmic transformation, the data were summarized as means plus SD from
five independent experiments. Expression in mock cells was used as a covariate. *,
p<0.05 versus CX3CR1 transfected control. 
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The R127N and S319X receptor variants were transfected in HEK293 cells using
lipofectamine. After 48 hours, cells were selected for receptor expression by G418. Only
cells that express the plasmid have the resistance for this antibiotic. After several days of
G418 preselection, mixed clones were diluted and seeded on a 96-well-plate at the
concentration of 1 cell/well. Single clones were grown and subsequently subcultivated.
Receptor expression was controlled using flow cytometry. Clones matching the
expression of CX3CR1-transfected HEK293 cells were chosen for further experiments
(Figure 24). 
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Figure 24: Stably transfected HEK293 cells. CX3CR1 and its R127N and S319X
variants were stably expressed in HEK293 cells and selected for comparable sur-
face expression by flow cytometry using PE-conjugated rat anti-CX3CR1. During
all further experiments, cells were constantly controlled for stable receptor expres-
sion. Data are shown as a representative histogram. 
Following ligand binding, most G-protein coupled receptors rapidly become
internalized which allows to control desensitization towards the ligand [Ben-Baruch et
al., 1995; Kraft et al., 2001]. To further examine the influence of conserved motifs on
receptor function, fluorescently labeled CX3CL1 chemokine domain that allows the
visualization of internalization processes was used. HEK293 cells expressing the
indicated receptor variants were incubated with 10 nM of AlexaFluor647-labeled
CX3CL1 chemokine domain for 5 - 30 minutes at 37°C. Immediately after stimulation,
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cells were kept on ice to avoid further internalization. As control that the fluorescence
increase was due to ligand uptake rather than ligand binding, aliquots of cells were
incubated under the same conditions, but in the continuous presence of NaN3 during the
whole experiment in order to prevent ligand uptake. 
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Figure 25: CX3CR1 internalizes upon CX3CL1 treatment and mediates
CX3CL1 uptake. (top) HEK293 cells expressing the different receptor variants
were incubated with AlexaFluor647-labeled CX3CL1 (AF-CX3CL1) at 37°C in the
absence or presence of NaN3 (0.2%). Subsequently, cells were analyzed for binding
and uptake of CX3CL1 by flow cytometric measurement of fluorescence. A repre-
sentative histogram of the fluorescence signal for CX3CR1-HEK293 cells is
shown. (bottom) HEK293 cells expressing the different receptor variants were incu-
bated with AF-CX3CL1 at 37°C for the time periods indicated. The fluorescence
intensity for the different HEK293 mutants was expressed in relation to that of the
control receiving no AF-CX3CL1, and is presented as mean ± SD from three inde-
pendent experiments. *, p<0.05 versus the untransfected control. ✝, p<0.05 versus
CX3CR1-HEK293 cells.
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As shown in Figure 25, expression of CX3CR1 or the R127N mutation led to a time-
dependent increase in fluorescence, as measured by flow cytometry. This increase was
almost completely abolished when cells were continuously treated with NaN3. No
specific fluorescence uptake was seen with wt-HEK293 cells, and increase in
fluorescence was clearly reduced when the S319X variant was expressed, indicating that
the receptor’s C-terminus contributes to receptor-mediated ligand uptake. 
Since the concentration of intracellular free calcium rapidly increases upon activation
of most chemokine receptors including CX3CR1 [Imai et al., 1997], I decided to test
whether the receptor variants were able to mediate intracellular calcium signals.
Therefore, HEK293 cells expressing the indicated receptor variants were loaded with the
fluorescent calcium indicator Fluo3-AM. While Fluo3-AM, in contrast to Fluo3, can
traverse the cell membrane, the molecule itself does not bind Ca2+. Once the dye is inside
the cell, it is hydrolyzed to Fluo3 by endogenous esterases. When bound to calcium
Fluo3 absorbs at 506 nm and emits at 526 nm [Kao et al., 1989; Minta et al., 1989]. This
signal can be measured in a fluorescence reader to visualize the intracellular calcium
flux. 
On stimulation with 10 nM CX3CL1 chemokine domain, HEK293 cells expressing
CX3CR1 showed a rapid increase of the fluorescence signal of about 0.25 mM Ca2+,
peaking at about 5 seconds after stimulation and lasting for about 30 seconds. Wt-
HEK293 cells or HEK293 cells expressing the R127N variant, however, did not show
any increase in fluorescence signal intensity, whereas the fluorescence signal of HEK293
cells expressing the S319X was slightly lower (about 0.2 mM Ca2+) than that of the
wildtype receptor (Figure 26) after treatment with soluble CX3CL1. These data indicate
that the induction of intracellular calcium transients by CX3CR1 requires the integrity of
the receptor’s DRY motif, but is independent of its C-terminus. 
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Figure 26: CX3CR1 and S319X, but not R127N mediate intracellular calcium
flux. HEK293 cells expressing the indicated receptor variants were loaded with cal-
cium indicator Fluo3-AM and changes in fluorescence intensity upon treatment
with soluble CX3CL1 chemokine domain (10 nM at 100 seconds) were recorded.
Loading was controlled using digitonin for maximal and EGTA for minimal signal.
Length of arrow indicates an increase of 0.5 mM Ca2+. Results shown are represen-
tative for three independent experiments. 
To explore the functional relevance of the R127N and S319X variants of CX3CR1 for
cell recruitment, stably transfected HEK293 cells were tested for their ability to adhere to
CX3CL1-expressing ECV304 cells and HUVEC under static and flow conditions. Wt-
ECV304 or CX3CL1-ECV304 cells were grown to confluency, and fluorescently labeled
HEK293 cells expressing the indicated receptor variants were either seeded onto the
layer for static adhesion or directed over the cell layer with a constant shear stress rate of
2 dyne/cm2 for adhesion under flow conditions. As shown in Figure 27, disruption of
conserved motifs in CX3CR1 did neither change its capability to mediate adhesion under
static conditions (AI = 7.35; 6.97 and 7.80, respectively) nor under flow conditions (AI =
13.34; 15.49 and 13.12, respectively). 
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Figure 27: Receptor variants mediate adhesion under static and flow condi-
tions. The ability of receptor variants to mediate adhesion to CX3CL1 was tested
under static (top) and flow (bottom) conditions. (top) For static adhesion assays,
calcein-labeled HEK293 cells expressing the indicated receptor variants were seed-
ed onto wt- or CX3CL1-ECV304 cells and after washing, the fluorescence signal of
the adhering cells was measured. (bottom) For flow adhesion experiments, labeled
HEK293 cells expressing the indicated receptor variants were perfused over a layer
of cytokine-stimulated HUVEC for 1 minute and adherent cells were counted. Data
are shown as mean ± SD of three independent experiments. *, p<0.05 versus the
untransfected control. 
Since calcium signals are required for proper migration, I expected that cells
expressing the R127N variant of CX3CR1 would not migrate towards CX3CL1. As
HEK293 cells did not show migration properties, it was decided to use the murine pre-B-
cell line L1.2 that was stably transfected with the indicated receptor variants. L1.2 cells
do not express endogenous CX3CR1, but are able to mediate migration towards
chemokines when transfected with chemokine receptors, as was previously indicated in
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section 5.2. L1.2 cells were transfected using the AMAXA system and selected with
G418. L1.2 cell clones expressing the receptor variants were chosen according to their
expression level similar to that of L1.2 cells stably expressing CX3CR1. 
Chemotaxis experiments were performed to investigate, whether the R127N and
S319X variants of CX3CR1 would allow migration in response to soluble CX3CL1. In a
modified Boyden chamber chemotaxis assay, only the CX3CR1-expressing cells (MI at
10 nM = 2.46), but not the cells with altered receptors migrated towards increasing
concentrations of CX3CL1 (Figure 28) (MI at 10 nM CX3CL1: R127N-CX3CR1 = 1.07
and S319X-CX3CR1 = 1.02). Again, 10 nM CX3CL1 was the optimal concentration for
induction of chemotaxis in CX3CR1-L1.2 cells. 
I then examined the ability of CX3CR1 variants to induce transmigration through the
ECV304 cell layer. When CX3CR1-L1.2 cells were seeded onto CX3CL1-ECV304
cells, transmigration was increased (TI = 2.51). By contrast, transmigration was even
below baseline when L1.2 cells expressed the R127N or S319X-mutant (TI = 0.28 and
0.25, respectively) (Figure 28). 
To confirm these data in a more physiologic setting, cell layers of cytokine-stimulated
HUVEC instead of ECV304 cells were used for transmigration assays. As seen in Figure
29, CX3CR1 expression increased transmigration of L1.2 cells (TI = 3.12), whereas the
expression of R127N-CX3CR1 suppressed transmigration (TI = 0.61) (S319X-CX3CR1
was not investigated). These results suggest that receptor function via the DRY motif and
the C-terminus are required for transmigration. In the absence of these motifs, however,
transmigration is blocked, which could be explained by the retention of leukocytes
adhering to transmembrane CX3CL1. 
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Figure 28: Receptor variants do not mediate (trans-)migration. The ability of
receptor variants to mediate migration (top) and transmigration (bottom) towards
CX3CL1 was tested. (top) L1.2 cells expressing the indicated receptor variants
were tested for their chemotactic response towards increasing concentrations of sol-
uble CX3CL1 (0.1 nM - 100 nM) in a modified Boyden chamber assay. (bottom)
L1.2 cells expressing the indicated receptor variants were studied for transmigration
through CX3CL1- ECV304 cell layers. Data are shown as mean ± SD of three inde-
pendent experiments. *, p<0.05 versus the untransfected controls (unstimulated or
untransfected and unstimulated). 
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Figure 29: Receptor variant R127N does not mediate transmigration through
HUVEC. HUVEC were stimulated with IFNγ and TNFα (both 10 ng/ml) for 16
hours and subsequently probed for transmigration of L1.2 cells expressing the indi-
cated receptor variants. Data are shown as mean ± SD of three independent experi-
ments. *, p<0.05 versus the untransfected control.
The extravasation process requires the cell to find an appropriate site for transcellular
diapedesis. When L1.2 cells expressing the indicated variants were co-incubated with wt-
or CX3CL1-ECV304, L1.2 cells expressing the wildtype receptor crawled on the cell
layer expressing CX3CL1 and extended pseudopods (69% of cells). Formation of
pseudopods might help the cells to find a site for transmigration and was not present
when the ligand was not expressed on the cell layer (13.52 to 14.51% of cells). When
L1.2 cells expressing the R127N or S319X-CX3CR1 variants were assayed, the
pseudopod formation rate was reduced (24.15% and 12.76% of cells, respectively)
(Figure 30). 
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Figure 30: Receptor variants do not mediate pseudopod formation. L1.2 cells
expressing the indicated variants were co-incubated with a wt- or CX3CL1-
ECV304 cell layer. For 5 minutes every 10 seconds a picture of a randomly chosen
field was taken. 100 cells per field were analyzed for pseudopod formation. In the
lower panel a representative formation of a pseudopod of a CX3CR1-L1.2 cell on a
CX3CL1-ECV304 cell layer is shown (white scale bars represent 3 µm). Data are
shown as mean ± SD of three independent experiments. The asterisk indicates sta-
tistically significant differences versus the untransfected control, p<0.05.
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5.4 Involvement of ADAMs in CX3CR1-CX3CL1 function 
I then questioned whether the activity of CX3CL1 sheddases on ECV304 cells is
required for transmigration towards CX3CL1. To address this issue, the ECV304 cell
layer was pretreated with GW280264X, an inhibitor of the metalloproteinases ADAM10
and ADAM17 that shed transmembrane CX3CL1 [Garton et al., 2001; Hundhausen et
al., 2003]. To selectively address the role of the proteases on the ECV304 cell layer, the
inhibitor was removed prior to starting the transmigration assay with the addition of L1.2
cells. As shown in Figure 31, the inhibitor did not affect L1.2 cell recruitment via soluble
CX3CL1 chemokine domain (TI = 1.78; DMSO control: TI = 1.82), but clearly blocked
transmigration in response to transmembrane CX3CL1 (TI = 0.97; DMSO control: TI =
1.66). Moreover, this inhibition of transmembrane CX3CL1 activity could not be
overcome by addition of soluble CX3CL1 chemokine domain as chemoattractant (TI =
1.21; control: TI = 1.66). Residual transmigration in the absence of CX3CL1 was not
affected by GW280264X, indicating that there was no general effect on the integrity of
the cell layer. These results indicate that the activity of ADAMs is only required for
transmigration in response to transmembrane CX3CL1, but not to soluble CX3CL1. 
The following set of experiments was performed to confirm the effect of the inhibitor
with PBMC. CX3CL1-ECV304 cells were coincubated in the absence or presence of
PBMC to investigate whether PBMC would affect CX3CL1 surface expression on the
ECV304 cells. Therefore, PBMC were seeded onto a ECV304 cell layer for 3 hours at
37°C and were then tested for their CX3CR1 surface expression in flow cytometry. To
differentiate between PBMC and ECV304 cells, cells were gated for size. The surface
expression level was reduced in the presence of PBMC (relative fluorescence intensity =
0.69) (Figure 32). Pretreatment of CX3CL1-ECV304 cells with GW280264X, however,
considerably increased CX3CL1 surface expression (relative fluorescence intensity =
3.26), which was not affected when the CX3CL1-ECV304 cell layer was exposed to
PBMC (relative fluorescence intensity = 3.40). 
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Figure 31: Pharmacologic inhibition of ADAM10/17 abrogates transmem-
brane CX3CL1-dependent L1.2 cell transmigration. Wt- or CX3CL1-ECV304
cells were grown on transwell inserts and pretreated with GW280264X (10 µM) or
DMSO control for 1 hour. After removal of the inhibitor, the lower compartments
of the transwell systems received soluble CX3CL1 chemokine domain (10 nM) or
were left without stimulus, and subsequently CX3CR1-L1.2 cells were assayed for
transmigration. Data are shown as mean ± SD of three independent experiments. *,
p<0.05 versus the mock-treated control.
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Figure 32: CX3CL1 surface expression is reduced when incubated with
PBMC. CX3CL1-ECV304 cells were pretreated with GW280264X (10 µM) or
DMSO for 1 hour, washed and then co-incubated with freshly prepared PBMC for
3 hours. Cells were harvested and analyzed for CX3CL1 surface expression by flow
cytometry. The mean fluorescence intensity was expressed in relation to that of
CX3CL1-ECV304 cells receiving no inhibitor and no PBMC and data are shown as
mean ± SD of three independent experiments. *, p<0.05 versus the control.
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Figure 33: PBMC adhere, but do not transmigrate towards CX3CL1 when
ADAM10/17 are inhibited. (top) Wt- or CX3CL1-ECV304 cells were pretreated
with DMSO as control or GW280264X (10 µM) for 1 hour, washed and subse-
quently analyzed for adhesion of PBMC under flow. (bottom) Wt- or CX3CL1-
ECV304 cells were grown on transwell inserts, pretreated with DMSO as control or
GW280264X (10 µM) for 1 hour and subsequently probed for transmigration of
PBMC. Data are shown as mean ± SD of three independent experiments. *, p<0.05
versus the mock-treated controls.
To examine whether the increased CX3CL1 surface expression after treatment with
the inhibitor would affect cell recruitment, adhesion assays were performed. CX3CL1-
mediated adhesion to ECV304 cells was considerably increased when the cells were
pretreated with the ADAM10/17 inhibitor (AI = 7.0; DMSO control: AI = 4.25) (Figure
33). However, despite increased CX3CL1 surface expression and increased CX3CL1-
mediated adhesion, CX3CL1-mediated transmigration through the ECV304 cell layer
was completely suppressed by the inhibitor (TI = 1.15; DMSO control: TI = 2.05)
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(Figure 33). Residual transmigration in the absence of CX3CL1 was not affected by
GW280264 (TI = 1.15). 
As shown in Figure 34, experiments were repeated with HUVEC, demonstrating that
PBMC adhesion to cytokine-stimulated HUVEC is profoundly increased (AI = 3.07;
DMSO control: AI = 2.01), whereas transmigration is completely suppressed by the
inhibitor (TI = 0.94; DMSO control: TI = 2.02). 
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Figure 34: PBMC adhere, but do not transmigrate towards CX3CL1 when
ADAM10/17 are inhibited. (top) HUVEC were stimulated with IFNγ and TNFα
(both 10 ng/ml) or left unstimulated for 16 hours, and were pretreated with DMSO
as control or GW280264X (10 µM) for 1 hour, washed and subsequently analyzed
for adhesion of PBMC under flow. (bottom) HUVEC were grown on transwell in-
serts, stimulated with IFNγ and TNFα (both 10 ng/ml) or left unstimulated for 16
hours, and were pretreated with DMSO as control or GW280264X (10 µM) for 1
hour and subsequently probed for transmigration of PBMC. Data are shown as
mean ± SD of three independent experiments. *, p<0.05 versus the mock-treated
control.
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The importance of ADAM10 and ADAM17 in CX3CL1-dependent transmigration
was further investigated by shRNA-mediated silencing of these proteases. Martin Hess of
our laboratory generated a lentiviral expression vector for shRNA that was used for
efficient and sustained downregulation of ADAM10 and ADAM17 surface expression on
ECV304 cells. By ELISA, he confirmed that silencing of ADAM10 led to a reduced
release of soluble CX3CL1 and accumulation of CX3CL1 in the cell lysates. Silencing of
ADAM17 had no comparable effect on the constitutive release of CX3CL1, which is
consistent with the previous observation that this protease is implicated in the PMA-
stimulated release of CX3CL1, but not in the constitutive shedding of the chemokine. 
CX3CR1-mediated transmigration through CX3CL1-expressing ECV304 cell layers
(TI = 1.95) was almost completely suppressed when ADAM10 expression was silenced
(TI = 1.02), and moderately reduced when ADAM17 expression was downregulated (TI
= 1.34) (Figure 35). 
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Figure 35: ADAM10, but not ADAM17 silencing leads to an almost complete
suppression of CX3CL1-mediated transmigration. Stably transduced CX3CL1-
ECV304 cells were investigated for transmigration of wt- and CX3CR1-L1.2 cells.
After washing, 2x105 L1.2 cells were seeded onto the confluent ECV304 cell layer
for 2 hours at 37°C. Subsequently, transmigrated cells were counted. A10 indicates
the transduction of CX3CL1-ECV304 cells with shRNA for ADAM10, and A17 in-
dicates the transduction with shRNA for ADAM17. Data are shown as mean ± SD
of three independent experiments. *, p<0.05 versus the untransfected control.
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These results indicate that the proteolytic activity of ADAM10, and to a lesser degree
of ADAM17, decreases CX3CL1 surface expression and CX3CL1-mediated adhesion
and is required for transmigration in response to CX3CL1.
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5.5 CXCR6-CXCL16 function 
CXCL16 shares a number of structural and functional properties with CX3CL1. It is
expressed as transmembrane variant and shed by ADAM10 resulting in a soluble
CXCL16 variant that mediates chemotaxis of CXCR6 expressing T-cells [Matloubian et
al., 2000; Abel et al., 2004]. When CXCR6 was analyzed for conserved motifs, a DRF
motif instead of a DRY motif was found in the second intracellular loop (Figure 21).
This alteration was already described for the 5-HT2βPan -receptor of Panulirus interruptus
(spiny lobster) and implicated in its constitutive activity [Clark et al., 2004]. This raises
the question which role the DRY(F) motif would play for the function of CXCR6.
To investigate the function of CXCR6, mononuclear cells from peripheral blood of
healthy donors were probed for CXCR6 expression by flow cytometry using a PE-
labeled antibody. CXCR6 was previously described to be expressed on CD4+ T-helper 1,
CD8+ T-cytotoxic and T-regulatory 1 subsets of T-cells, smooth muscle cells, dendritic
cells, B-cells, macrophages and subsets of natural killer cells [Matloubian et al., 2000;
Sharron et al., 2000; Kim et al., 2001; Wilbanks et al., 2001; Hofnagel et al., 2002; Sato
et al., 2005]. Depending on donor and cell type, the expression level highly varied from
nearly absence of detectable CXCR6 expression and high CXCR6 expression. For all
donors the strongest expression of CXCR6 could be seen on T-cell subsets (Figure 36). 
A fundamental step in leukocyte recruitment is the firm adhesion on the endothelium
lining the blood vessel. CXCR6, expressed on T-cells, has been reported to be involved
in CXCL16 mediated T-cell recruitment to inflammatory sites [Galkina et al., 2007].
Freshly prepared PBMC from donors expressing high or low levels of CXCR6 were
tested for their adhesion to CXCL16-expressing cell layers under static conditions. When
PBMC were co-incubated with CXCL16-ECV304 cells and subsequently washed, no
adhesion could be observed. This effect was independent from the level of CXCR6
expression (low expression: AI = 0.85, high expression: AI = 0.93, control: AI =
1.0)(Figure 37).
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Figure 36: CXCR6 expression varies based on donor. Freshly isolated blood
mononuclear cells of healthy donors were probed for their expression of CXCR6
using a PE-labeled anti-hCXCR6 antibody. The grey shaded curve represents the
isotype control, the black unshaded curve represents hCXCR6 expression of not
gated PBMC. Donor A expresses CXCR6 on PBMC subsets (left), whereas no
CXCR6 was detected on PBMC of donor B (right). Data are shown as a representa-
tive histogram. 
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Figure 37: PBMC do not adhere to CXCL16 under static conditions. Freshly
isolated PBMC from donors with a high or low expression of CXCR6 were assayed
for adhesion under static conditions on wt-ECV304 or CXCL16-ECV304 cell layer.
PBMC were stained with CalceinAM for 15 minutes. Excess dye was removed by
washing, cells were suspended to a concentration of 5x105 cells/ml and seeded onto
wt- or CXCL16-ECV304 cells. After washing, the fluorescence signal of the adher-
ing cells was measured. Data are shown as mean ± SD of three independent
experiments. 
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Due to the high variability of CXCR6 expression on PBMC, I then tested HEK293
cells stably expressing CXCR6 for their ability to adhere to CXCL16 expressing cells
under static conditions. Wt-ECV304 or CXCL16-ECV304 cells were grown to
confluency, and fluorescently labeled wt-HEK293 and CXCR6-HEK293 were seeded
onto the cell layer. As shown in Figure 38, no adhesion of CXCR6 expressing cells to
CXCL16 expressing cells could be observed under static conditions (AI = 1.7; control:
AI = 1.0). 
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Figure 38: CXCR6-expressing cells do not adhere to CXCL16 under static
conditions. Wt-HEK293 and CXCR6-HEK293 cells were assayed for adhesion un-
der static conditions on wt-ECV304 or CXCL16-ECV304 cell layer. HEK293 cells
were stained with CalceinAM for 15 minutes. Excess dye was removed by wash-
ing, and cells were suspended to a concentration of 5x105 cells/ml and seeded onto
wt- or CXCL16-ECV304 cells. After washing, the fluorescence signal of the adher-
ing cells was measured. Data are shown as mean ± SD of three independent
experiments. 
As CXCL16 is described to bind to CXCR6, I performed a binding assay with 6xHis-
tagged recombinant CXCL16 chemokine domain. Cells were incubated with
CXCL16-6xHis in the absence or presence of a 10 fold excess of CXCL16 chemokine
domain. Bound CXCL16-6xHis was then detected with an anti-6xHis-tag-antibody.
When PBMC of a donor with high expression of CXCR6 were analyzed, binding was
found that could be diminished by competition with untagged CXCL16 chemokine
domain. In contrast, PBMC from donors with a low expression of CXCR6 did not bind
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CXCL16-6xHis (Figure 39). 
Figure 39: CXCR6 binds CXCL16-6xHis. CXCL16 binding to PBMC was ana-
lyzed by flow cytometry using recombinant 6xHis-tagged CXCL16 chemokine do-
main as ligand in the absence or presence of a 10-fold excess of untagged CXCL16
chemokine domain. The binding was detected using a murine anti-6xHis-tag-anti-
body and an anti-mouse-PE antibody. The pink curve represents the untreated con-
trol, the blue curve represents detected binding of 6xHis-tagged CXCL16 on
PBMC and the green curve represents 6xHis-tagged CXCL16 binding when un-
tagged CXCL16 is present for competition. Donor A expresses CXCR6 on PBMC
subsets (left), whereas no CXCR6 was detected on PBMC of donor B (right).
Results shown are representative for three independent experiments. 
Albeit its inability to mediate adhesion, there remains the possibility that the binding
of CXCL16 to CXCR6 would mediate chemotaxis. Freshly prepared PBMC were
assayed for chemotaxis in response to soluble CXCL16 chemokine domain (1 - 100 nM)
in a modified 48-well Boyden chamber setting. When PBMC highly expressing CXCR6
were used, increased migration could be observed (MI = 1.85 at 10 nM CXCL16).
Chemotaxis towards CXCL16 chemokine domain was dose-dependent and showed the
characteristic bell shaped curve reported for chemokines peaking at 10 nM soluble
CXCL16 chemokine domain (Figure 40). Based on this curve, all further experiments
were performed with 10 nM soluble CXCL16 chemokine domain. In contrast, when
CXCR6 expression could not be detected on PBMC, no migration towards CXCL16
chemokine domain was observed (MI = 0.98 at 10 nM CXCL16). These data indicate
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that CXCR6-mediated signaling of chemotaxis occurs despite of the alteration of the
conserved DRY motif into DRF. 
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Figure 40: PBMC expressing CXCR6 chemotactically migrate towards
CXCL16. PBMC were seeded onto a polycarbonate membrane with 8 µm pores in
a modified Boyden Chamber setting. 1-100 nM soluble CXCL16 chemokine do-
main were used to excite chemotaxis for 2 hours at 37°C. Subsequently, migrated
cells were counted. (left) Donor A expressed CXCR6 on PBMC subsets, whereas
no CXCR6 was detected on PBMC of donor B (right). Data are shown as mean ±
SD of three independent experiments. *, p<0.05 versus the unstimulated control. 
For a better understanding of the DRF motif in CXCR6 function, different receptor
variants were created: the DRF motif was changed into DNF (R127N) consistent with
the CX3CR1 experiments, and the DRY motif (F128Y) was reconstituted. The cDNA for
CXCR6 variants was constructed using two-fragment ligation and cloned into
pcDNA3.1+ expression vector. All constructs were successfully cloned and confirmed by
sequencing. 
To determine whether the mutated CXCR6 variants would be expressed, HEK293
cells were transiently transfected and tested for expression of CXCR6 using flow
cytometry. As shown in Figure 41, all constructed variants could be readily detected on
the cell surface of HEK293 cells 2 days after transfection. The expression level of
CXCR6 seemed not to be influenced by the alteration.
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Figure 41: Surface expression and ligand binding of CXCR6 variants. (left)
Expression of the receptor variants was controlled by flow cytometry using a PE-
conjugated anti-CXCR6 antibody. (right) Ligand binding was analyzed by flow cy-
tometry using a recombinant CXCL16-6xHis construct as a ligand. The binding
was detected using a murine anti-6xHis-tag-antibody and an anti-mouse-PE anti-
body. The grey shaded curve represents unstained wildtype HEK293 cells, the pink
curve represents the stained mock transfected control, the blue curve represents
stained CXCR6 transfected cells, the green curve represents stained R127N variant
transfected cells, and the orange curve represents stained F128Y variant transfected
cells. Data are shown as a representative histogram. 
Since ligand binding can be affected by mutating CXCR6, transiently CXCR6-
transfected HEK293 cells were tested for binding of a recombinant CXCL16-6xHis
construct. No differences in ligand binding could be observed between the wildtype
receptor and its variants (Figure 41).
To test whether the variants of CXCR6 are still able to mediate intracellular calcium
transients, HEK293 cells expressing the indicated receptor variants were loaded with the
fluorescent calcium indicator Fluo3-AM. On stimulation with 10 nM CXCL16, HEK293
cells expressing CXCR6 showed a calcium signal of about 0.05 mM Ca2+, peaking at
about 10 seconds after stimulation and lasting for about 45 seconds. Wt-HEK293 cells or
HEK293 cells expressing the R127N variant, however, did not show any signal.
Interestingly, the calcium signal of HEK293 cells expressing the F128Y variant was
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slightly decreased (about 0.04 mM Ca2+) compared to the response of cells expressing the
wildtype receptor (Figure 42). These data indicate that the induction of intracellular
calcium transients by CXCR6 requires the arginine residue of the receptor’s DRF motif,
but the phenylalanine residue is less critical. 
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Figure 42: CXCR6 and F128Y, but not R127N mediate intracellular calcium
flux. HEK293 cells expressing the indicated receptor variants were loaded with cal-
cium indicator Fluo3-AM and changes in fluorescence intensity upon treatment
with soluble CXCL16 chemokine domain (10 nM at 100 seconds) were recorded.
Loading was controlled using digitonin for maximal and EGTA for minimal signal.
The length of the arrow indicates an increase of 0.25 mM Ca2+. Results shown are
representative for three independent experiments. 
To explore the functional relevance of the R127N and F128Y mutations for cell
recruitment, stably transfected HEK293 cells were tested for their ability to adhere to
CXCL16-expressing ECV304 cells under static conditions. As shown in Figure 43,
changing the DRF motif in CXCR6 did not enable the receptor to mediate adhesion
under static conditions (AI = 0.93; 0.75 and 0.85, respectively). 
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Figure 43: R127N and F128Y do not adhere to CXCL16-ECV304 cells.
HEK293 cells expressing the indicated receptor variants were assayed for adhesion
under static conditions to wt-ECV304 or CXCL16-ECV304 cell layer. HEK293
cells were stained with CalceinAM for 15 minutes. Excess dye was removed by
washing and cells were suspended to a concentration of 5x105 cells/ml and seeded
onto wt- or CXCL16-ECV304 cells and after washing, the fluorescence signal of
the adhering cells was measured. Data are shown as mean ± SD of three indepen-
dent experiments. 
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6 Discussion 
The multi-step process of leukocyte extravasation starts with the rolling of leukocytes
on the activated endothelium, leading to flow-resistant adhesion to transmembrane
adhesion molecules. Subsequently, leukocytes transmigrate through the endothelium
towards a gradient of chemotactic molecules, such as formyl peptides, complement
factors and especially chemokines that belong to the class of cytokines. CX3CL1 and
CXCL16 are exceptional chemokines that are expressed as transmembrane molecules on
the surface of physiologic interfaces such as endothelial or epithelial cells. Both
chemokines can be shed by members of the ADAM family of metalloproteinases,
resulting in a soluble form and are implicated in several pathophysiological situations
such as HIV-infection, renal diseases and atherosclerosis [Tong et al., 2000; Furuichi et
al., 2001; Greaves et al., 2001; Galkina et al., 2007]. 
Transmembrane CX3CL1 is known to promote flow resistant adhesion of leukocytes
to endothelial or epithelial cells, which is mediated by physical interaction with its
receptor CX3CR1 independently from signaling via Gi-proteins [Fong et al., 1998].
Furthermore, CX3CL1 mediates chemotaxis of CX3CR1-expressing cells, like
monocytes, via Gi-protein activation and CX3CR1 signaling [Imai et al., 1997]. The
present study extends these findings by the detailed analysis of the influence of the
CX3CR1-CX3CL1-interaction during transmigration, internalization, signaling and
cleavage. It could be shown that transmembrane CX3CL1 that is expressed by
endothelial cells is sufficient to promote adhesion and transmigration. Analysis of
receptor mutants indicated that transmigration requires the internalization of the ligand-
receptor-complex as well as signaling of the receptor. Additionally, activity of
ADAM10/17 that shed transmembrane CX3CL1 was needed for efficient transmigration.
Based on the results a model of CX3CL1-mediated leukocyte extravasation is proposed. 
This thesis expands previous findings by showing that leukocytes not only employ the
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receptor CX3CR1 to bind and adhere to endothelial CX3CL1, but also for transmigration
of adherent leukocytes. This transmigration could be induced by the presence of
transmembrane or soluble CX3CL1, but not further enhanced by the presence of both
forms. Pretreatment of the endothelial cell layer with a neutralizing antibody to CX3CL1
abrogated CX3CL1-induced transmigration of peripheral blood mononuclear cells
(PBMC). Thus, CX3CR1/CX3CL1 interaction was necessary for leukocyte
transmigration. Application of inhibitory antibodies to ICAM-1 and VCAM-1, two major
adhesion molecules involved in leukocyte adhesion, led to a reduced level of CX3CL1-
mediated transmigration. It has been previously reported that inhibition of VCAM-1 on
activated endothelial cells reduced C5a-induced transmigration of monocytes, while
inhibition of ICAM-1 does not [Chuluyan and Issekutz, 1993]. However, CX3CR1
expression on stably transfected L1.2 cells did not activate integrin-mediated adhesion to
VCAM-1 [Haskell et al., 1999], whereas soluble CX3CL1 induced ICAM-1 expression
in endothelial cells [Yang et al., 2007]. The adhesion of CX3CR1 positive cells to
endothelial cells was previously shown to be ICAM-1-dependent [Yang et al., 2007].
Since the pretreatment of endothelial cells with inhibitory antibodies to VCAM-1 and
ICAM-1 abolished CX3CL1-mediated transmigration to a similar extent, not only
ICAM-1 but also VCAM-1 appear to contribute to CX3CL1-induced transmigration.
As in a transmigration assay with stimulated (and thoroughly washed) HUVEC as cell
layer, the transmigration of responsive cells was comparable to that obtained with
ECV304 cells, I asked if sufficient soluble CX3CL1 is produced to mediate
transmigration within the duration of the assay. As was shown by ELISA, the amount of
soluble CX3CL1 after 2 hours in both compartments of the transwell system was
comparable to that produced by unstimulated HUVEC. Since this quantity is not
sufficient to induce chemotaxis of PBMC or L1.2 cells it is unlikely that transmigration
is mediated by soluble CX3CL1. This data indicates a crucial role for transmembrane
CX3CL1 in the transmigration process.
In a transmigration assay with an inhibitory antibody against CX3CL1 that was
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applied baolaterally and/or apically, it could be shown that transmigration was
predominantly mediated by apically expressed transmembrane CX3CL1, whereas the
inhibition of basal transmembrane CX3CL1 did not affect transmigration. This result is
consistent with the fact that immobilized chemokines can induce haptotactic migration of
responsive leukocytes, and that a concentration gradient of soluble chemokine is not
required for this activity [Rot and von Andrian, 2004]. 
Furthermore, the pretreatment of CX3CR1-expressing cells with soluble CX3CL1
abolished CX3CL1-mediated transmigration. This effect was either due to
internalization, and therefore desensitization of the receptor towards CX3CL1, or due to
binding site occupancy. 
Endocytosis of ligand-receptor complexes plays a vital role in signal termination and
receptor resensitization, and is mediated by intracellular phosphorylation of the receptor,
and β-arrestin-binding with subsequent uncoupling of G-proteins. Internalization by
clathrin-coated vesicles eventually leads to the dissociation of the ligand and
dephosphorylation of the receptor. It is still under discussion whether internalized
receptor-ligand-pairs still signal or receptor resensitization enhances ligand-induced
signaling. Once the receptor is recycled back to the cell surface, it is resensitized and
competent to signal again [Wolfe and Trejo, 2007]. Dynasore is a small molecule
inhibitor of dynamin, which is essential for the formation of clathrin-coated vesicles. Just
recently it has been shown that dynasore prevents the CCL2-mediated endocytosis of
CCR2 [García Lopez et al., 2009]. Since pretreatment with dynasore inhibited
transmigration towards CX3CL1, it is very likely that internalization of the receptor
plays a crucial role in CX3CR1/CX3CL1-mediated transmigration. 
As internalization seemed to be important for transendothelial migration, I next
established receptor variants to analyze the molecular determinants for this receptor
function. Therefore, a highly conserved region in G-protein coupled receptor superfamily
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implicated in internalization of the receptor, namely NPX2-3Y in the seventh
transmembrane region, was changed into APLIY and NPLIA. Additionally, a truncation
mutant was constructed that lacked all C-terminal serine residues that can become
phosphorylated and interact with β-arrestins [Barak et al., 1994]. These receptor variants
were then stably transfected into HEK293 and L1.2 cells. Both cell lines did not express
CX3CR1 endogenously. Although HEK293 cells were previously described to migrate
[Dijkstra et al., 2004], no migration of CX3CR1-transfected cells towards CX3CL1
could be observed, but CX3CR1-expressing HEK293 cells adhered as efficiently as
PBMC to CX3CL1-expressing cells. Consistently, CX3CR1-transfected L1.2 cells
showed similar migration properties towards CX3CL1 compared to PBMC. These results
justify the use of both cell lines as a model system for CX3CR1-CX3CL1-interaction. 
The mutational analysis of the regions revealed that they are not required for surface
expression, but for ligand binding and trafficking of the receptor, respectively. The
NPX2-3Y motif of CX3CR1 is needed for ligand binding, as it has been reported for
some G-protein coupled receptors, like type 1 angiotensin II receptor [Hunyady et al.,
1995]. In contrast, in other G-protein coupled receptors, like β2-adrenergic receptor, the
NPX2-3Y motif is implicated in internalization, but not ligand binding [Barak et al.,
1995]. Ligand binding takes place at the receptor's N-terminus that ends in the first
transmembrane domain, and also on extracellular loops [Harrison et al., 2001]. Since the
NPX-3Y motif is located in the seventh transmembrane domain, which does not bind the
ligand directly, the loss of ligand binding is most likely due to sterical changes, as the
seventh transmembrane domain is located adjacent to the first [Palczewski et al., 2000]. 
Most chemoattractant receptors including CXCR2 and CCR5 carry a number of serine
residues that become phosphorylated upon ligand engagement and may trigger the
interaction with β-arrestin which in turn mediates receptor desensitization and
internalization [Ben-Baruch et al., 1995; Kraft et al., 2001]. Accordingly, deletion of the
serine-rich C-terminal part of CX3CR1 attenuated ligand uptake by internalization, but
not calcium signaling. In line with the observation that internalization plays an important
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role in the transmigration process, CX3CL1-mediated (trans-)migration of L1.2 cells
expressing the truncation variant of CX3CR1 was impaired. Thus, the C-terminus
contributes to trafficking, but not to induction of intracellular calcium transients.
 
Lucas and coworkers previously showed that Gi-protein inhibition abrogates
CX3CL1- mediated chemotaxis [Lucas et al., 2003]. Accordingly, pretreatment of
CX3CR1-L1.2 cells with the Gi-protein inhibitor pertussis toxin resulted in the
suppression of transmigration. These findings indicate that CX3CL1-induced
transmigration critically depends on Gi-protein signaling. From previous studies it is
known that the calcium response of G-protein coupled receptors depends on the DRY
motif and its interaction with Gi-proteins [Lagane et al., 2005; Berchiche et al., 2007].
Additionally, the arginine residue of this region has been shown to have effects on
receptor expression, internalization, and binding of the gonadotropin-releasing hormone
receptor [Arora et al., 1997; Ballesteros et al., 1998]. A CX3CR1 variant with a DNY
instead of the DRY motif was constructed, stably expressed in HEK293 and L1.2 cells,
and analyzed. As expected, the induction of intracellular calcium transients upon
treatment with soluble CX3CL1 was abolished in cells expressing the receptor variant.
As (trans-)migration of CX3CR1-R127N expressing cells is impaired, calcium-signaling
is essential for CX3CR1-mediated (trans-)migration. Apparently, this rapid calcium
response occurs independently of slower processes such as receptor internalization.
Taken together, the DRY motif of CX3CR1 is critical for the activation of calcium
signals, but contrary to other reports for different class A GPCR not for receptor
trafficking, as assessed by studying ligand uptake. 
Probing of the cell substrate in order to find an appropriate site for transmigration is a
crucial part in the extravasation process of leukocytes and was previously described for
neutrophils in response to the chemoattractant N-formyl-methionyl-leucyl-phenylalanine
[Alteraifi and Zhelev, 1997]. When L1.2 cells were co-incubated with wt- or CX3CL1-
ECV304 cells, L1.2 cells expressing the wildtype receptor extended pseudopods on the
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CX3CL1-expressing cell layer. This behavior could not be seen on wt-ECV304 cell
layers or by L1.2 cells expressing no CX3CR1 or the R127N and S319X variants. Both,
intracellular calcium signaling and F-actin network rearrangement are required for
efficient migration, although different signaling pathways seem to be involved. It has
been described that clathrin-deficient cells show an increase in turning and roundness,
and a decrease in polarity, velocity and chemotaxis-efficiency suggesting a role for the
suppression of pseudopod formation and stability [Wessels et al., 2000]. Thus, CX3CR1/
CX3CL1 interaction and the distinct coupled signaling processes are necessary for
pseudopod formation as an initial step of transmigration.
 
Although the DRY sequence as well as the C-terminus of CX3CR1 differentially
contribute to signaling and trafficking, they are both required for the induction of
chemotaxis and transmigration. The importance of the DRY motif may be explained by
the fact that it represents a critical motif for Gi-protein activation, which triggers
phospholipase C activation followed by diacylglycerol formation and calcium
mobilization. This signaling pathway is involved in the control of actin polymerization,
which is important for cell migration [Murdoch and Finn, 2000; Samstag et al., 2003]. In
murine CX3CR1, the DRY motif may have a similar function, as indicated by the finding
that its mutation into DNY blocks chemotaxis towards soluble CX3CL1 [Haskell et al.,
1999]. The integrity of the receptor’s C-terminus is required for receptor desensitization
via endocytosis, as shown for other chemokine receptors such as CXCR2 [Ludwig et al.,
1997] and clathrin-mediated signaling. This may explain why both Gi-protein activation
by the DRY motif as well as receptor regulation at the C-terminus are critical for
induction of chemotaxis by soluble CX3CL1. The data furthermore demonstrate that
both motifs are required for transmigration in response to transmembrane CX3CL1
suggesting that they may fulfill very similar functions in chemotaxis and transmigration.
Consistent with previous publications showing that adhesion does not require signaling,
adhesion is neither affected by mutating the DRY motif nor by truncation of the C-
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terminus [Fong et al., 1998; Haskell et al., 1999].
Transmembrane CX3CL1 can be cleaved proximal to the cell membrane resulting in
the release of its soluble ectodomain and the downregulation of CX3CL1 from the cell
surface [Garton et al., 2001; Hundhausen et al., 2003]. This effect on the one hand leads
to reduced adhesiveness for CX3CR1-expressing leukocytes via transmembrane
CX3CL1. On the other hand, leukocytes bound to transmembrane CX3CL1 may become
released upon cleavage of the transmembrane chemokine [Hundhausen et al., 2007].
Such a process could be relevant for transmigration when adherent leukocytes move
from the apical site of the endothelium towards the lateral junction for transmigration
between two substrate cells and would require the detachment from the apical side
including the interruption of the initial contacts between leukocytes and endothelial cells.
Since the binding of CX3CL1 to its receptor is extremely tight due to a low dissociation
rate from the receptor and a rather high average bond strength, cleavage of CX3CL1
might be the only way to disrupt the cell-cell contact and thereby allow transmigration
[Haskell et al., 2000; Lee et al., 2004]. 
In the present work, it was demonstrated that activity of ADAM10 and ADAM17 was
required for CX3CL1-induced transmigration. For this purpose, ADAM10 and ADAM17
were inhibited by using pharmacologic inhibitors and shRNA. It could be shown that the
application of the inhibitor led to an increased surface expression and a reduced shedding
of CX3CL1. While the blockade of shedding resulted in an enhanced adhesive activity of
CX3CL1, transmigration of CX3CR1-expressing L1.2 cells towards CX3CL1 was
dramatically reduced, as was shown for ECV304 cells as well as cytokine-stimulated
HUVEC. This data support the model that not only signaling and internalization of the
receptor are crucial for facilitating transmigration, but also the cleaving activity of
ADAM10 and ADAM17. It has been shown earlier that the inhibition of shedding of cell
adhesion molecules, like L-selectin (ADAM17) and VE-Cadherin (ADAM10), decreases
transmigration of T-cells [Faveeuw et al., 2001; Schulz et al., 2008]. Metalloproteinase
activation and activity could be one step in a cascade of events required for lymphocytes
6 Discussion
94
to extravasate the blood vessel. Thereby, ADAMs might not only regulate the
degradation of apical adhesion complexes, but also the loosening of adherens junctions,
as was shown for the VE-cadherin/α-catenin/β-catenin/plakoglobin complex that was lost
from adherens junctions at sites of monocyte penetration of the endothelial layer and
rapidly regained after transmigration [Allport et al., 2000]. 
Extravasation of leukocytes out of the bloodstream is thought to take place in a multi-
step process that starts with rolling onto endothelial cells via selectins, turns into
chemokine-mediated firm adhesion to adhesion molecules such as integrins, and ends
with the migration of leukocytes towards chemotactic factors through the endothelial
barrier [Springer, 1994]. These events can be mediated by coordinated activity of
selectins, chemokines and integrins. Unlike other chemokines, CX3CL1 has the capacity
to mediate capture under flow, tight adhesion and directional transmigration. Therefore,
it could contribute to all steps of the recruitment process. From this study, I would like to
propose that the process of CX3CL1-mediated cell recruitment involves a sequence of
events starting with physical binding of the receptor, activation of the receptor initiating
the transmigration process, and ending with the cleavage of CX3CL1 by ADAM10 and
ADAM17 allowing the cells to proceed in diapedesis. The last step of transmigration
may involve the cleavage of several surface molecules that contribute to the
transmigration process such as VCAM-1, JAM-A and VE-cadherin, and very likely also
the shedding of transmembrane CX3CL1 [Pruessmeyer and Ludwig, 2008]. 
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Figure 44: Proposed model. Based on the findings presented in this thesis, a mod-
el concerning the involvement of CX3CR1/CX3CL1 interaction in the extravasa-
tion process can be proposed. Expression of transmembrane CX3CL1 is induced by
the activation of the blood vessel lining endothelium on the luminal as well as the
abluminal membrane. While PBMC (and especially monocytes) roll on the en-
dothelium due to interactions with selectins, they can be captured not only by clas-
sical adhesion molecules, like ICAM-1 and VCAM-1, but also by transmembrane
CX3CL1. Acting as a signaling receptor, CX3CR1 might mediate important signals
for the transmigration process. In order to find an appropriate site to extravasate,
PBMC have to probe the tissue they are adhering to. Therefore, bonds have to be
dissolved and others closed. Important molecules in dissolving the bond between
endothelial cell and leukocyte formed by CX3CR1 and CX3CL1 are the metallo-
proteases ADAM10 and ADAM17. Additionally, they cleave unoccupied CX3CL1
forming a gradient of soluble chemokines and dissolving complexes between en-
dothelial cells facilitating leukocyte transmigration.
The data provide a molecular explanation for the proinflammatory activity of the
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CX3CR1/CX3CL1 axis in vascular diseases such as atherosclerosis, which is well
documented by a number of recent studies using CX3CR1- or CX3CL1-deficient mice
[Combadière et al., 2003; Lesnik et al., 2003; Teupser et al., 2004]. Finally, when
considering the CX3CR1/CX3CL1 axis as a therapeutic target in order to block
leukocyte recruitment in atherosclerosis, it seems preferable to interfere with the initial
step of adhesion using a receptor antagonist rather than blocking CX3CR1 signaling or
CX3CL1 shedding, which would both lead to the accumulation of adherent leukocytes at
the vascular surface. 
In the future a set of further experiments should be conducted to elucidate the role of
CX3CR1/CX3CL1 in the extravasation process. It is known that β-arrestins are
important for the internalization of G-protein coupled receptors and subsequent signaling
and interact with the intracellular part of the receptor [Kraft et al., 2001]. Additionally,
some reports show that CX3CL1 and CX3CR1 are involved in survival and proliferation
signals in microglia, epithelial cells and smooth muscle cells in a NF-κb-dependent
manner [Boehme et al., 2000; Brand et al., 2002; Chandrasekar et al., 2003]. Since both,
the DRY sequence as well as the C-terminus of CX3CR1 are required for transmigration,
the analysis of other pathways would possibly lead to a better understanding of signaling
pathways, other than intracellular calcium flux, involved in CX3CR1/CX3CL1 function. 
There are two possibilities to analyze the involvement of CX3CR1/CX3CL1-mediated
adhesion and transmigration: first, the construction of a signaling-deficient receptor
variant and second the construction of a non-cleavable ligand variant. As it is known that
ADAMs are able to employ a vast number of different cleavage sites, the construction of
a non-cleavable ligand variant seemed to be more difficult than that of receptor variants.
Still, it would be a great help to have a CX3CL1 variant that can not be cleaved, and this
project should be pursued with different approaches. 
As was shown earlier, the CX3CR1/CX3CL1 axis is involved in the progression of
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inflammatory diseases like atherosclerosis [McDermott et al., 2001; Moatti et al., 2001]
and nephropathies [Furuichi et al., 2001; Cockwell et al., 2002]. In further experiments
the CX3CR1 variants should be analyzed in inflammatory models in vivo. Therefore, the
receptor has to be reconstituted in CX3CR1-deficient mice by either knock-in technique
or by lentiviral transfer. This will help to evaluate the magnitude and manner of
contribution of CX3CR1/CX3CL1 in the extravasation process of leukocytes during
inflammation. 
CXCL16 and its receptor CXCR6 are implicated in a multitude of pathophysiological
situations as atherosclerosis and HIV infection [Deng et al., 1997; Matloubian et al.,
2000; Galkina et al., 2007]. Recent data from studies using mice deficient in either
CXCR6 or CXCL16 support a role for both ligand and receptor in atherogenesis
[Aslanian and Charo, 2006; Galkina et al., 2007]. 
When peripheral blood mononuclear cells (PBMC) of healthy donors were tested for
expression of CXCR6, it was surprising that the expression of CXCR6 strongly varied
depending on the donor and cell type. Consequently, PBMC from CXCR6low-
expressing donors did not migrate in response to CXCL16 whereas PBMC from donors
showing an expression of CXCR6 migrated towards CXCL16. Surprisingly, unlike
published earlier [Shimaoka et al., 2004], CXCR6-expressing cells did not adhere to
CXCL16-expressing cells. Just recently it was shown that stimulated macrophages do not
adhere to coronary artery smooth muscle cells in a CXCL16-dependent manner under
static conditions [Barlic et al., 2009]. The differential receptor expression and the non-
adherence of CXCR6-positive cells raised the question whether the adhesion of CXCR6-
expressing cells to CXCL16-expressing cells is relevant under physiological conditions.
For other adhesion molecules, shear stress on endothelial cells is important for the
mediation of firm adhesion. Shear stress has been shown to modulate the adhesive
capacity of endothelial cells by adjusting the expression of adhesion molecules as for
example ICAM-1 [McKinney et al., 2006]. Therefore, flow assays are needed to
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elucidate the possibility that CXCL16 only induces adhesion under flow conditions.
Furthermore, a network of interactions might be necessary for the CXCR6-CXCL16
interaction to become relevant under physiological conditions.
Instead of the highly conserved DRY motif found in many chemokine receptors,
CXCR6 bears a DRF motif within the second intracellular loop. This DRF motif is also
found in the 5-HT2βPan -receptor of Panulirus interruptus (spiny lobster) and implicated in
its constitutive activity [Clark et al., 2004]. The DRF motif in the Gonadotropin releasing
hormone receptor (GnRH-R) of Callithrix jacchus (common marmoset) mediates a
slightly faster internalization rate than the DRS motif found in GnRH-R of most
mammals [Byrne et al., 1999]. When the DRF motif of CXCR6 was changed into the
conventional DRY, only slight changes in calcium signaling could be observed, whereas
the mutation into DNF abolished the calcium signal. As seen for CX3CR1, the arginine
residue seems to play the crucial role in the mediation of calcium signals, whereas the
tyrosine residue does not contribute. The tyrosine residue is believed to be a potential
phosphorylation site, acting as a substrate for a G-protein receptor kinase, and thus is
important for receptor desensitization and internalization [Palczewski, 1997]. This
suggestion was supported by the findings of a study carried out by Arora and colleagues,
which demonstrated that mutating the serine to a tyrosine in the mouse GnRH-R
increased the rate of receptor internalization and agonist binding affinity, although no
effect was observed on G-protein coupling [Arora et al., 1995]. However, it has also been
shown that generating a mouse GnRH-R DRS to DRA mutation had no significant
effects on ligand binding, receptor coupling or internalization [Arora et al., 1997].
Therefore, for functional analysis the next step should be the investigation of
internalization rates after binding of CXCL16 to CXCR6, similar to the experiments
done for CX3CR1 variants.
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Additionally, knock-down of CXCR6 led to the formation of medullablastoma,
suggesting a role in cancer development [Sasai et al., 2007]. The interaction of CXCR6
and CXCL16 is also thought to mediate cell recruitment in rheumatoid arthritis, and
CXCR6 acts as secondary co-receptor for all HIV-strains [Liao et al., 1997; Ruth et al.,
2006]. In upcoming experiments the interaction of CXCR6 and CXCL16 should be
further characterized. Therefore, L1.2 cell expressing CXCR6 and its variants, consistent
with the experiments for CX3CR1 in this thesis, should be generated and analyzed in
(trans)-migration and other functional assays, like phosphorylation of signaling
molecules or mediation of proliferation/survival.
While CXCR6 is thought to be a pro-atherogenic chemokine receptor, as its knock-
down resulted in a decrease of susceptibility to atherosclerosis, CXCL16 might be
atheroprotective due to the fact that its knock-down resulted in accelerated
atherosclerosis, which has been associated with the additional scavenger receptor
function of the chemokine. CXCL16 not only binds to CXCR6 to mediate cell
recruitment, but also acts as scavenger receptor for oxidized low density lipoproteins.
This function of CXCL16 is not influenced by CXCR6. The uptake of low density
lipoproteins eventually leads to an upregulation of atheroprotective genes, such as ATP-
binding cassette transporter-1 and apolipoprotein E [Liao et al., 2002; Barlic et al., 2009].
This supports the hypothesis that CXCL16 mediates atheroprotection not through the
interaction of CXCR6 and CXCL16, but through its scavenger function. Antagonism of
the CXCR6-CXCL16 interaction without affecting the scavenger receptor activity may
be of therapeutic potential. 
Although both chemokines exist as soluble as well as transmembrane forms, the
functions they mediate on binding to their receptors seem to differ. While CX3CR1
mediates adhesion as well as migration, CXCR6 only mediates migration. The
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experiments showed that transmembrane CX3CL1 contributes to the extravasation of
leukocytes, while there is no contribution of transmembrane CXCL16. To obtain a better
understanding of the underlying mechanisms receptor variants were generated. Although
the CX3CR1 (and to a lesser degree the CXCR6) variants were extensively
characterized, some questions remain open and should be addressed in a future set of
experiments. The importance of the C-terminal part of CX3CR1 was shown in the
context of receptor desensitization but it is still unclear what pathways and functions
exactly are affected. Therefore, experiments targeting the receptor phosphorylation at
intracellular serine-residues, receptor recycling or F-actin network rearrangement should
be performed. Additionally, the unusual DRF motif in CXCR6 might influence the
receptor's activity turning it into a constitutively active receptor in contrast to receptors
bearing the conserved DRY motif. The consequence of such a potential constitutive
activity in the context of chemotaxis should be investigated. Furthermore, the impact of
CX3CL1 and CXCL16 shedding still remains unclear even though it was shown that the
activity of the sheddases is required for efficient CX3CL1-mediated transmigration. With
the variety of mediated functions, the CX3CR1-CX3CL1 axis, and possibly also
CXCR6-CXCL16, may constitute important regulators involved in leukocyte
extravasation. 
As all the presented data were generated in vitro, these results should be confirmed by
in vivo experiments. Despite their different structural characteristics and activity,
CX3CR1 and CXCR6 show a pro-atherogenic potential as confirmed by usage of knock-
out mice for CX3CR1 and CXCR6 [Combadière et al., 2003; Galkina et al., 2007]. These
mice can now be reconstituted with the mutated murine receptors by knock-in technique
or lentiviral genetransfer as is currently established in our laboratory. The impact of the
alteration of conserved motifs in CX3CR1 and CXCR6 should be investigated in the
context of inflammatory animal models, such as the ApoE-/- diet-induced atherosclerosis
or wire-induced injury model. In the latter model, CX3CL1 is upregulated in intimal
smooth muscle cells and endothelial cells. Furthermore, CX3CR1 deficiency is
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associated with a decreased infiltration of monocytes [Liu et al., 2006]. The relevance of
CX3CR1-CX3CL1 axis in humans is underlined by the fact that the CX3CR1
polymorphism V249I is associated with increased monocyte adhesiveness increasing the
risk for restenosis after coronary stent implantation [Daoudi et al., 2004; Niessner et al.,
2005]. Accordingly, the alteration of the DRY motif of CX3CR1 or truncation of the C-
terminal serine-residues can have the following impact in a murine model of
inflammation: cells expressing the CX3CR1 variants, that both block transmigration,
should accumulate on the arterial wall and the infiltration into the lesion should be
reduced. 
Similarly, in a model of ApoE-/- diet-induced atherosclerosis, mice deficient in CXCR6
display reduced atherosclerosis associated with a lower content of CXCR6+ T cells and
macrophages in the aorta [Galkina et al., 2007]. Since CXCR6-dependent chemotaxis
requires signaling, less cells expressing the receptor variants should be recruited into the
lesion, when the DRF motif is abolished. In contrast to CX3CL1, CXCL16 does not
mediate adhesion. Therefore, as indicated by the in vitro experiments, cells expressing
the mutated DRF motif of CXCR6 should not accumulate at the vascular wall. Thus,
mutating either receptor should result in a less severe inflammatory response. This may
be complicated by the fact that mutated CX3CR1 still functions as adhesion molecule
leading to an accumulation of CX3CR1-variant expressing cells at the arterial wall. A
pharmacological interference with transmembrane CX3CL1 should block both, the
accumulation of leukocytes at the site of inflammation and their infiltration into the
lesion.
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Fig. figure
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I-κK I-κB kinase complex
IL interleukin
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JAM junctional adhesion molecule
JNK c-Jun N-terminal kinases
K
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L
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M
M molar
mAb monoclonal antibody
Mac-1 macrophage antigen-1
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mRNA messenger ribonucleic acid
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NF-κB nuclear factor 'kappa-light-chain-enhancer' of activated B-cells
O
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ox-LDL oxidized low density lipoprotein
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PBMC peripheral blood mononuclear cell
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PECAM platelet/endothelial cell adhesion molecule
Pen/Strep penicillin/streptomycin
PFA paraformaldehyde
pfu Pyrococcus furiosus
PI3K phosphoinositide 3-kinase
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PIP2 phosphatidylinositol 4,5-bisphosphate
PKB proteinkinase B
PKC proteinkinase C
PLC phospholipase C
PMA phorbol-12-myristat-13-acetat
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P-selectin platelet selectin
PTX pertussis toxin
R
RANTES regulated upon activation, normal T-cell expressed, and secreted
RNA ribonucleic acid
rpm rounds per minute
RPMI roswell park memorial institute
RT room temperature
S
s second
SAPK stress-activated phospho-kinases
SD standard deviation
SDS sodiumdodecylsulfate
SH3 Src-homology 3
shRNA short interfering RNA
SIV simian immunodeficiency viruses
Src sarcoma
SR-PSOX scavenger receptor that binds phosphatidylserine and oxidized 
lipoprotein
SOB super optimal broth
T
TACE tumor necrosis factor alpha converting enzyme
Taq Thermus aquaticus
TECK thymus-expressed chemokine
TI transmigration index
TNF tumor necrosis factor
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U unit
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V
VCAM vascular cell adhesion molecule
VE-Cadherin vascular endothelial cadherin
VLA-4 very late antigen 4
W
wt wildtype
X
X-gal bromo-chloro-indolyl-galactopyranoside
A  alanine (Ala)  G  glycine (Gly)  M methionine (Met) S   serine (Ser)
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11 Vectors
11.1 hCX3CR1 in pcDNA3.1+
11 Vectors
123
11.2 hCX3CR1 R127N in pcDNA3.1+
11 Vectors
124
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11.7 hCXCR6 R127N in pcDNA3.1+
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